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Magnetic materials are of interest for biomedical applications for the ability to remotely
control magnetic particles through the use of non-invasive magnetic fields. Specific applica-
tions of magnetic materials in biomedical fields include magnetic resonance imaging, drug
delivery, or hyperthermia-based cancer treatments. The most commonly used material for
these applications are iron oxides, which suffer from acute toxicity and unknown fate in
vivo and thereby limit their applications.
An alternative approach is to substitute magnetic ions into a biocompatible and biodegrad-
able material to impart magnetic properties. Hydroxyapatite, the main inorganic component
of natural bone, is widely studied as a biomaterial for its excellent biocompatibility and
osteoconductivity. The crystal structure of HA is highly flexible allowing for a wide range
of substitutions for tailoring material properties. Hydroxyapatite with magnetic properties
may be an alternative to iron oxides for the aforementioned applications. Iron, cobalt,
and manganese substituted hydroxyapatite powders were synthesized via ion exchange
and characterized to verify successful substitution into the lattice. All substitutions were
successfully prepared and resulted in ion-substituted hydroxyapatite with magnetic proper-
ties. Experimental results were also in good agreement with theoretical calculations which
predicted manganese substituted hydroxyapatite to have the largest magnetic moment.
The synthesized magnetic hydroxyapatites are shown to be biocompatible making them
suitable for magnetic resonance imaging and drug delivery applications while providing a
biodegradable and biocompatible alternative to iron oxides for these applications.
Michael Zilm – University of Connecticut, 2016
Magnetic materials have also been used in tumor therapy applications. For tumor therapy
applications the materials blood circulation time is desired to be as long as possible to
enhance accumulation at the tumor site. Semi-flexible filomicelles have been shown to have
significantly longer circulation times than rigid spheres or rods. Type I collagen, the main
organic phase of bone, is a filamentous protein and semiflexible polymer that allows for
mineralization within specific zones of the fiber. Through self-assembly and bio-templating
we have developed a method to induce mineralization of iron oxide within collagen fibers
to form a flexible and magnetic "nanoworm" for tumor therapy applications.
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CHAPTER ONE
Introduction
1.1 Magnetic Materials for Biomedical Applications
Magnetic materials have attracted significant interest as a multi-functional material for
biomedical applications.[1–7] The ability to "remotely" control magnetic particles using
non-invasive magnetic fields allows for targeted delivery applications where a magnetic
field manipulates a magnetic particlein situ. This property is advantageous for magnetic res-
onance imaging (MRI) contrast enhancement, targeted drug delivery, cancer hyperthermia,
and cell stimulation and magnetic separation applications.[1, 2, 4, 7–10]
The magnetic properties of a material dictate its application. Figure 1.1 depicts different
magnetic responses to an applied magnetic field. Diamagnetic materials create an opposing
magnetic field that results in a negative slope. In paramagnetic materials, magnetic
moments align with an applied magnetic field resulting in a small magnetization that
vanishes upon removal of the applied magnetic field. For ferri- and ferro-magnetic materials
the response is characterized by a rapid increase in magnetization and eventual saturation
of the magnetic moment; upon removal of the magnetic field a permanent, remanent,
magnetization remains. The ideal material for biomedical applications would have zero
magnetization in the absence of a magnetic field but a large magnetization in the presence
of a low magnetic field.This behavior is desired because if there is a remanent magnetization,
particles would aggregate due to magnetic dipole interactions. Superparamagnetic materials
fit into this description, Figure 1.1 (d). While superparamagnetic materials are ideal for
all aforementioned applications, paramagnetic and ferri- or ferro-magnetic materials are
also suitable for certain applications. Table 1.1 outlines the suitable magnetic properties for
different applications.
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Figure 1.1: Magnetization (M) of different type of magnetic materials under an ap-
plied magnetic field (H). Diamagnetic (a), paramagnetic (b), ferromagnetic (c), and
superparamagnetic (d).
Table 1.1: Summary of the magnetic properties required for different biomedical appli-
cations where magnetic properties are desired/needed.
Application Required Magnetic Properties
Magnetic Separation Superparamagnetic Ferromagnetic
Cell Stimulation Superparamagnetic Ferromagnetic
(twisting force) (pulling force)
Targeted Drug Delivery Superparamagnetic
MRI Contrast Agent Paramagnetic Superparamagnetic
(T1 imaging) (T2 imaging)
Hyperthermia Superparamagnetic
1.1.1 Magnetic Separation
Purification of proteins and cells is typically achieved through expensive liquid chro-
matography techniques.[11, 12]Magnetic separation provides a simple and efficient tech-
nique to isolate valuable cells or proteins in a single vial. The particles are functionalized
with a targeting agent to selectively bind to the cell/protein of interest and a strong mag-
netic field is applied to collect magnetically labeled cells/proteins.[13, 14] This separation
technique can be employed numerous times to improve purification. Magnetic particles
have been used to isolate hematopoietic stem cells from peripheral blood by labeling mag-
netic particles with antibody CD34 to isolate CD34-positive mononuclear blood cells.[15]
In clinical applications labeled magnetic particles may be added to a patients sample to aid
in diagnosis of diseases. For example immuno-magnetic particles are capable of detecting
one tumor cell per 107 peripheral blood mononuclear cells.[16] Magnetic particles must
2
have a large magnetization to be effective for this application, but it provides a simple, cost
efficient, and highly effective tool to isolate cells/proteins in expressed in low quantities.
1.1.2 Magnetic Stimulation
Tissues are a dynamic material that respond to internal and external stimuli. Mechanical
stimuli is an often studied external stimuli that is known to initiate signaling pathways and is
required for production of certain proteins in bone, cartilage and muscle cells.[17] Bone for
instance requires cyclic loading for proper function.[18] Mechanical stimuli causes a cellular
response through the activation of mechanosensitive ion channels or the deformation and
activation of the cell membrane and cytoskeleton.[9] The typical forces exerted on cells
in vivo is on the order of 10-12 to 10-9 Newtons which is the same order of magnitude
that external magnetic fields can exert on magnetic nanoparticles allowing for magnetic
stimulation of cells.[18, 19]
The ability to manipulate these channels using magnetic micro- or nanoparticles allows
for in vitro investigations of cell function and molecular signaling pathways. Magnetic ma-
nipulation is achieved by functionalizing magnetic particles to attach to specific membrane
receptors and applying magnetic fields to create a translational (pulling) force or torque
(twisting) directly to the cell. Through quantification of ion channel kinetics the biochemical
pathways associated with these receptors can be elucidated.[18] Ion channel activation
using magnetic beads was suggested that endothelial cell stiffening was mediated through
Rac- or Cdr42hs-dependent pathways.[20] Magnetic actuation has also been used for cel-
lular conditioning in the field of tissue engineering and regenerative medicine. Magnetic
nanoparticles functionalized to target TREK-1 receptors in human bone mesenchymal stem
cells (HBMSCs) have been shown in vitro to up regulate gene expression of osteopontin
and Cbfa1.[21]
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1.1.3 Targeted Drug Delivery
In drug delivery "a pharmaceutical compound is administered to achieve a therapeutic
effect."[22] Often times, a specific area is of interest for therapy and targeting is achieved via
passive or active targeting approaches. Passive delivery relies on diffusion and convection to
deliver the therapeutic agent, while targeted approaches utilize targeting ligands to increase
retention of the therapeutic agent at the target site.[23] Neither of these approaches
provide site-directed targeting to the area of interest. Magnetic delivery systems offer
‘remote’ control over the delivery vehicle, where an external magnetic field is applied to
guide the magnetic delivery vehicle to the site of interest. Figure 1.2 depicts the concept of
magnetic delivery.
Figure 1.2: The concept of magnetic delivery where an externally applied magnetic field
is used to guide magnetic particles to the site of interest.
In magnetic delivery systems, magnetic particles are surface functionalized to impart
colloidal stability, allow attachment of therapeutic agents to the magnetic particle, and
allow detachment under an applied stimuli. After administration of the magnetic delivery
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system external magnetic fields are applied with high gradients to accumulate the magnetic
particles at a specific site; subsequently the drug is released.[24, 25] This approach is often
applied for tumor therapy where conditions associated with the tumor microenvironment
are used induce drug release such as pH and enzymatic degradation.[24] Heat generated
through the application of an alternating magnetic field may also be applied for drug release
when thermosensitive polymers are employed for surface functionalization.[25]
Magnetic targeting has been shown to be successful in laboratory experiments and
preclinical practice.[26–29] Schleich et al. compared the passive, active, magnetic, and
combination of magnetic and active targeting ability of superparamagnetic iron oxide
nanoparticles for tumor therapy.[27] The combination of magnetic and active delivery
resulted in the largest accumulation of iron oxide in the tumor followed by magnetic, active,
and passive targeting respectively.[27] Magnetic targeting was shown superior to passive
targeting, when magnetic targeting was used to accumulate polyethylene glycol modified
cross-linked starch coated iron oxide nanoparticles for brain tumors.[28] Magnetic targeting
is a promising approach but requires high magnetic field gradients to overcome convective
drag forces. Alexiou et al. used a 1.7 Tesla magnetic field in the region of a tumor surface
to successfully treat squamous cell carcinoma in rabbits.[29] The effectiveness of magnetic
targeting is largely dictated by the strength of the magnetic field gradient and the volumetric
and magnetic properties of the particles.
1.1.4 MRI Contrast Agents
MRI is a widely used clinical tool for the assesment/diagnosis of soft tissue and tumors.
Imaging is achieved by monitoring the relaxation time of nuclear magnetic spins of protons
in water, in particular, and contrast is achieved as result of the different relaxation times
between different types of tissue. Imaging is performed utilizing T1 or T2 relaxation. In
T1 weighted images, differences in longitudinal relaxation (the time for spins to realign
with the magnetic field) of tissues are used to provide contrast, and T2 weighted images
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differences in transverse relaxtion (the time for spins to dephase) are utilized for contrast.
But, the differences in relaxation times between tissues are often small making diagnosis
difficult at times.[30]
Contrast can be enhanced through the use of a contrast agent. Most commonly para-
magnetic complexes, such as gadolinuium (3+) or manganese (2+) chelates, are used to
enhance T1 relaxation, and superparamagnetic iron oxide nanoparticles are used to enhance
T2 relaxation.[31] T1 contrast agents result in an increase in brightness, while T2 contrast
agents decrease brightness.
Current T1 contrast agents are limited because of the small size of Gd3+ and Mn2+
chelates to the detection of the breakage of the blood brain barrier, changes in vasculartiy,
flow dynamics, and changes in perfusion.[32] While the resulting dark signal from T2-
weighted images can make diagnosis difficult, because the signal make be confused with
artifacts such as bleeding or hard tissue.[32]
The ideal contrast agent would provide both T1 and T2 contrast enhancement where
both imaging modalities can be used in conjunction for more accurate diagnosis. Current
strategies for imparting T1 and T2 enhancement involve: synthesis of ultra-small metal oxide
nanoparticles or the combination of a T1 and T2 contrast agent in a single system.[33–37]
Wang et al. synthesized a pH responsive nanogel containing manganese oxide and iron
oxide nanparticles. Under an acidic condition, the dissolution of manganese oxide results
in the release of manganese ions results in positive T1 contrast enhancement, while the
iron oxide nanoparticles provide positiveT2 contrast enhancement.[33] While Wang et al.
achieved a dual responsive T1 and T2 contrast agent by reducing the size of iron oxide
nanoparticles to less than 2 nm.[34] The small size of the nanoparticles resulted in a large
surface that increases the number of interactions between water molecules and surface iron
ions which decreased T1.[34] Susceptibility effects from iron oxide result in local magnetic
field inhomogeneity which decreases T2.[34]
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1.1.5 Hyperthermia
Hyperthermia is a cancer treatment where elevated temperatures are used to kill
malignant cells. In a typical treatment, heat is generated by applying a specific absorption
rate (SAR (W/kg)) to the tumor via, microwaves, radiofrequency, ultrasound, or alternating
magnetic fields to increase and maintain the temperature in the tissue around 41-42 ◦C.[38]
This temperature range has been successful in killing malignant cells, because malignant
cells are more temperature sensitive than normal cells where irreversible damage does
not occur until 45 ◦C.[39] Spatiotemporal temperature control is essential for effective
hyperthermia treatment and is difficult to achieve with microwaves, radiofrequency and
ultrasound. [38] Magnetic hyperthermia has been promising, since it utilizes dispersed
magnetic particles allowing the specific tissue of interested to be targeted and heated.[38]
Superparamagnetic iron oxide nanoparticles are often used for hyperthermia treatments.
Heat is generated through either Néel’s or Brownian relaxation mechanisms under the
application of an alternating magnetic field with a frequency of a few hundred kHz and
amplitude of a few kA/m. The rate at which heat is generated (SAR) can be controlled
through modulation of the physical and chemical properties of the magnetic material.[40–
42] The heat generating characteristics can be used in conjunction with other magnetic
biomedical applications such as targeted drug delivery for more effective treatments.[43] For
this effect, hyperthermia has been used to increase the effects of chemotherapy treatments.
The temperature elevation aids in increasing the permeability of the tissue, which is
advantageous for increased extravasation of nanoparticles into the tumor resulting in more
efficient delivery of chemotherapeutics.[44, 45]
1.1.6 Current Issues with Magnetic Particles
The most widely used magnetic materials for biomedical applications are γ-Fe2O3 and
Fe3O4. The high magnetization, ease of synthesis, and the high dietary need of iron
has made these materials lucrative for biomedical applications. For clinical applications
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where long circulation times are needed these materials are surface functionalized with
ampiphilic or charged moieties to prevent protein adsorption. After functionalization these
materials are considered well tolerated because rapid clearance through extravasation,
renal clearance, and mechanical filtration removes the majority of nanoparticles within 24
hours.[46] But poor biodegradation and acute toxicity of iron oxides have raised concerns
over the application of iron oxides in medical applications.[47]
Uncoated iron oxide nanoparticles are non-degradable, cytotoxic, and are believed to
support the formation of reactive oxygen species (ROS), which have damaging effects on
cells.[48] Removal of iron oxide is accomplished by internalization by cells to degrade the
particles under acidic conditions to free iron ions.[49] This can lead to an excess of iron in
the organs and result in iron overload or the formation of damaging ROS species. In vitro
studies have shown iron oxide nanoparticles functionalized with negatively and positively
charged functional groups are less toxic than uncoated nanoparticles, but still cytotoxic.
[50] While moderate levels of Fe2O3 nanoparticles have been shown to adversely affect
neuron function in vitro and displayed a dose dependent reduction on cell viability.[51] In
other non-immunogenic cells iron oxides have shown to have dose dependent toxicity that
adversely affects mitochondrial function, membrane leakage of lactate dehydrogenase, and
result in genotoxicity and chromosome condensation.[48, 52]
There also concerns over short and long term in vivo toxicity where nanoparticles
distribute into various essential organs. Some clinically available iron oxide nanopar-
ticles coated with dextran are prone to the dextran detaching during circulation.[52]
Uncoated particles are prone to aggregation which can block blood flow and result in
embolism.[53, 54] The distribution of particles in vivo have shown particles to accumu-
late in other organs such as the brain where the long term effect of these particles are
uncertain.[49] The development of an inherently biodegradable and biocompatible mag-
netic particle may minimize short and long term toxicity concerns with functionalized iron
oxide nanoparticles.
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1.2 Hydroxyapatite
To circumvent the issue of biodegradation and acute toxicity, biocompatible materials
may be doped with magnetic ions to impart magnetic properties. An ideal material is
hydroxyapatite (HA) (Ca10(PO4)6(OH)2) the mineral phase of bone and a well-documented
biomaterial known for its excellent biocompatibility. Synthetic HA is widely used in biomed-
ical applications such as a filler for bone replacement, drug delivery, tissue engineering
scaffolds, and as a bioactive coating.[55, 56]
1.2.1 Hydroxyapatite Substitutions
The crystal structure (space group P63/m) of HA is highly flexible accommodating a wide
range of ionic substitutions. The materials and biological properties of HA can be altered
through substitutions of Sr, Mg, K, Ba, Cu, or Fe for Ca and CO32-, Cl, or F for OH.[57–59]
Another property, which may be altered, is the magnetic properties. HA is diamagnetic in
nature but recently it has been shown that substituting magnetic impurities into HA results
in paramagnetism or superparamagnetism.[60–63]
1.2.2 Magnetic Substitutions
The most commonly used metal for imparting HA with magnetic properties is iron.[60,
63–65] The choice of iron as a dopant stems from its high daily dietary need and its large
magnetic moment. Many more elements have the potential to yield magnetic HA with
varying levels of bioactivity and magnetization. When considering potential magnetic
impurities, the magnetic moment of the ion must also be considered. Ideally ions that have
the largest moment, are biocompatible, and have a high solubility in the HA lattice should
be used for substitution.
The magnetic moment of an element is related to the number of unpaired electrons and
orbital contributions to the magnetic moment depending upon the oxidation state. The
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magnetic moment of an ion can be calculated by:
µS+L =
√
4S(S + 1) + L(L+ 1)µB (1)
where S is the spin quantum number, L is the angular quantum number, and µB is
Bohr magneton. In the case where spin-orbit coupling (Russel-Saunders coupling), which
adequately describes lanthanides, is present the moment is calculated by:
µ = gJ
√
J(J + 1)µB, gJ =
3
2
+
S(S + 1)− L(L+ 1)
2J(J + 1)
(2)
where J is the total angular momentum, L ± S, and gJ is the Landé g-factor.
Figure 1.3: High spin (right) and low spin (left) electron configurations for Fe2+ or for
ions with [Ar]3d6 electron configurations
The local chemical environment can also affect the net moment depending upon how
the crystal field splits the d-orbitals, while f-electrons are too far inside to be affected by
the crystal field. When the crystal field splitting energy is small or comparable to the spin
pairing energy, the electrons fill the orbitals to maximize the number of unpaired spins
(high spin), but when the crystal field splitting energy is larger than the spin pairing energy,
electrons fill the lowest energy orbitals first (low spin). For example Fe2+ in an octahedral
crystal field can exhibit high spin or low spin depending upon the energy of the crystal field
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Table 1.2: Maximum calculated and observed magnetic moments of transition metal
ions in an octahedral environment
Ions Electron
Config.
Calculated
Moment
(µB)
Observed Moment(µB)
Ti3+ V 4+ [Ar]3d1 1.73 1.6-1.7 1.7-1.8
V 3+ Cr4+ [Ar]3d2 2.83 2.7-2.9 2.8
V 2+ Cr3+ Mn4+ [Ar]3d3 3.88 3.8-3.9 3.7-3.9 3.8-4.0
Cr2+ Mn3+ [Ar]3d4 4.90 4.7-4.9 4.6-5.0
Mn2+ Fe3+ [Ar]3d5 5.92 1.6-1.7 1.7-1.8
Fe2+ [Ar]3d6 4.90 5.1-5.7
Co2+ [Ar]3d6 3.87 4.3-5.2
Ni2+ [Ar]3d6 2.83 2.9-3.3
Cu2+ [Ar]3d6 1.73 1.7-2.2
splitting, the electron configuration is depicted in Figure 1.3.
Considering the geometry of the calcium sites in HA, which are distorted octahedral
[66] any orbital contribution to the magnetic moment is most likely quenched, and the
contribution to the magnetic properties can be attributed to spin only moments, which can
be calculated by:
µS =
√
4S(S + 1)µB (3)
Table 1.2 lists the maximum (high spin) calculated magnetic moments of various transition
metal ions, and Table 1.3 lists the maximum calculated magnetic moments of trivalent
lanthanide ions that are possible substituents.
The ions with the highest magnetic moments are from the lanthanides with electron
configurations from [Xe]4f7 to [Xe]4f12 whose moments range from 7.56 to 10.65 µB. Dy3+
has the highest calculated moment at 10.65 µB followed by Ho3+ with 10.6 µB. Despite these
promising magnetic moments, many of the lanthanides are toxic in free ion form.[67, 68]
Gd3+ with a calculated moment of 7.94 µB is widely used as a T1 MRI contrast agent, but is
used in a chelated form to prevent toxicity with Gd3+ leaching being a concern.[69] Due
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Table 1.3: Maximum calculated and observed magnetic moments of trivalent lanthanides
Ion Electron
Config.
Calculated
Moment (µB)
Observed
Moment
(µB)
La3+ [Xe]4f 0 0 0
Ce3+ [Xe]4f 1 2.54 2.3-2.5
Pr3+ [Xe]4f 2 3.58 3.4-3.6
Nd3+ [Xe]4f 3 3.62 3.5-3.6
Pm3+ [Xe]4f 4 2.68 –
Sm3+ [Xe]4f 5 0.85 1.4-1.7
Eu3+ [Xe]4f 6 0 3.3-3.5
Gd3+ [Xe]4f 7 7.94 7.9-8.0
Tb3+ [Xe]4f 8 9.72 9.5-9.8
Dy3+ [Xe]4f 9 10.65 10.4-10.6
Ho3+ [Xe]4f 10 10.6 10.4-10.7
Er3+ [Xe]4f 11 9.58 9.4-9.6
Tm3+ [Xe]4f 12 7.56 7.1-7.6
Y b3+ [Xe]4f 13 4.54 4.3-4.9
Lu3+ [Xe]4f 14 0 0
to the toxicity of these elements, the lanthanides were not considered as substituents for
magnetic HA.
Since many transition metals are required for normal biological function, the transition
metal with electron configurations with [Ar]d3 through [Ar]d7 give rise to maximum
calculated magnetic moments ranging from 3.88 to 5.92 µB. Of these ions, Mn2+, Fe3+, Fe2+,
and Co2+ were selected as possible substituents for magnetic HA. Magnetic HA is a potential
alternative to iron oxide in applications related to MRI contrast enhancement and drug
delivery applications as well as a material for bone repair and regeneration applications.
1.3 Requirements for Tumor Therapy
In regards to tumor therapy applications, the particle properties such as size and shape
are important factors.[70–73] In both passive and targeted delivery applications the blood
circulation time is an important factor in particular accumulation at the tumor site. There
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is increasing evidence that non-spherical/anisotropic particles are less readily taken up
by macrophages prolonging circulation.[72, 73] Non-spherical shapes also demonstrate
improved targeting efficiency, since the oblong shapes can form more binding events
compared to spherical particles.[73] While in circulation, non-spherical particles exhibit
more lateral drift compared to spherical particles which follow streamlines which results in
an increased likely hood of accumulating at the tumor site.[73] Also, particles of discoidal
shape have been shown to have less accumulation in the liver than spherical particles.[74]
Mullner et al. studied the influence of size, shape, and rigidity on the circulation time
and bio-distribution of cylindrical polymer brushes (CPBs).[75] As the length of CPBs
increases the CPBs plasma residence time decreased, but t1/2 of 20 hrs was still observed
for the longest CPBs which were ∼ 1.2 µm.[75] With an increase in length more CPBs were
deposited in mononuclear phagocytic system (MPS).[75] Interestingly, when the stiffness
of the CPBs were increased the clearance rate increased and more material was cleared by
the liver when compared to flexible CPBs of the same length.[75]
Recently the stiffness of the delivery vehicle was shown to influence blood circulation
time. Discher’s group showed that long semi-flexible filomicelles displayed excellent tumor
targeting ability and blood circulation times as a result of the flexible and fragment-able
nature of the filomicelles.[76–78] The in vivo performance of peglyated spherical micelles
was compared to semi-flexible filomicelles. In a rodent model persistent circulation of semi-
flexible filomicelles was observed for more than 7 days compared to spherical micelles which
were cleared in 3 days.[76] During this time period greater accumulation of filomicelles
was observed in the tumor compared to spherical micelles administered at the same
concentration.[76] The enhanced performance was attributed to the semi-flexible nature of
the filomicelles where upon penetration into a tumor the filomicelle may fragment as a result
of shear forces. The fragmentation process kept hydrolysable filomicelles with a length of 8
µm and width of 60 nm in circulation for up to 8 days.[76] Due to size, shape, and enhanced
circulation filomicelles were more efficient at the delivery of an anti-cancer drug, taxol,
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allowing for a larger maximum tolerable dose. Compared to spherical micelles, filomicelles
were shown to incorporate twice as much anti-cancer drug, taxol. Theoretical calculations
were also performed on the interaction between taxol and filomicelles/spherical micelles,
suggesting that filomicelles are able to retain more taxol due to their shape.[77] These
physiochemical properties of semi-flexible filomicelles also resulted filomicelles having
a twice the maximum tolerated dose of taxol that of spherical micelles.[78] Apotosis in
non-tumor organs was 13-15 % less when filomicelles were administered compared to
micelles.[78] These observed effects were attributed to the large size, long circulation, and
fragmentation of filomicelles. Under shear flow the filomicelles may fragment into a size
large enough to avoid clearance by the MPS organs but small enough to extravasate into
the tumor. This behavior helps reduce apoptosis in vital organs ultimately increasing the
maximum tolerated dose.[78] Overall the work conducted by the Dishcer group [76–78]
highlights the importance of size, shape, and stiffness on the in vivo performance of delivery
vehicles for cancer therapy.
Magnetic nanoworms, which are a linear chain of iron oxide spheres, have been synthe-
sized through the precipitation of magnetite in the presence of dextran with a length of ∼
50 nm and width of ∼ 5 nm.[79] Park et al. hypothesized that the anisotropic structure
would result in improved circulation and ability of the nanoworms to target and image
tumors.[79] The in vivo evaluation demonstrated that these nanoworms had similar blood
circulation times to iron oxide nanospheres, t1/2 of 17 hours for nanoworms compared to
t1/2 of 18 hours for nanospheres. Retention of nanoworms within the tumor was observed at
48 hours post administration whereas a high percentage of nanospheres have been cleared
from the tumor at 48 hours. The retention behavior was attributed to the larger size of the
nanoworms which increases the difficulty to extravasate out of the tumor.[79] The shape
of these nanoworms improved tumor targeting ability. Through optimizing a conjugated
targeting ligand to the nanoworms improved uptake and increase the targeting efficiency
were observed.[80] Nanoworms conjugated with the targeting ligand had twice the tumor
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uptake of nanospheres with the targeting ligand.[80] The magnetic property of iron oxide
also render the materials suitable for magnetic resonance imaging (MRI) applications.
Wang et al. synthesized magnetic nanoworms using the method by Park et al.[79] with a
length of ∼ 250 nm and width of ∼ 7 nm and assessed the magnetic nanoworms as a MRI
contrast agent.[81] Compared to a commercially available spherical iron oxide based MRI
contrast agent nanoworms displayed an excellent transverse relaxivity R2 of 455 mM-1s-1
compared to 100 mM-1s-1 for feridex.[81]
The main organic component of bone is type I collagen which is a long and flexible
filamentous protein. The polymerization of collagen monomers into collagen fibers results
in regions of overlap and gaps within the fiber. Within the field of biomineralization it
has been demonstrated that HA can be selectively deposited in the gap zone of collagen
fibers.[82–84] Inspired by this structure, the deposition of an inorganic magnetic phase
within the gap zone of collagen fibers may yield a semi-flexible and magnetic material that
can be used for tumor targeting applications. The combination of these materials allows
for a potential magnetic material with long blood circulation time that may be used for
the detection and treatment of tumors through MRI, targeted drug delivery, and cancer
hyperthermia.
1.4 Objectives
The objective of the research here is to (a) predict potential transition metal substituents
for magnetic HA that would yield the largest magnetic moment, (b) synthesis and charac-
terization of different magnetic HA in particular manganese-, iron-, and cobalt-substiuted
HA, (c) in vitro assessment of magnetic HA, and (d) develop a method to mineralize col-
lagen fibers with iron oxide for the synthesis of magnetic nanoworms for tumor therapy
applications. For objective (a) HA was chosen for substitution with transition metals to
impart magnetic properties due to the well-known biocompatibility of HA along with its
ability to accept a wide range of substituents.
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Initially, theoretical calculations were performed to aid in the selection of substituents
and confirm successful substitution with experimental data. From the theoretical calcula-
tions the following divalent transition metals: manganese, iron, and cobalt were selected as
substituents. Substituted HA was synthesized by performing an ion-exchange with pure
HA. All substitutions resulted in paramagnetic properties with no detection of a second
phase. Many transition metals have multiple stable oxidation states, as such trivalent iron
and pentavalent manganese. Iron substituted HA was further synthesized using Fe3+ and a
combination of Fe2+ and Fe3+. Fe3+HA displayed paramagnetic properties, while Fe2+3+HA
displayed a combination of magnetic responses of Fe2+HA and Fe3+HA. Manganese has been
reported to positively influence in vitro activity in particular by promoting cell attachment
and may be well suited as a bioactive bone substitute material. The sintering behavior and
mechanical properties of MnHA were compared to that of pure HA to assess MnHA for other
bone tissue engineering applications. Since the synthesized transition metal substituted
HA’s are intended for biomedical applications, in vitro evaluation was performed to assess
the biocompatibility of the different substituted HA powders. All substituted apatites were
biocompatible with iron and manganese not significantly effecting cell behavior.
The magnetic properties of the synthesized magnetic HA are well suited for MRI contrast
and targeted delivery applications, but the rigid nature of the magnetic HA may result
in poor circulation times and may not be well suited for tumor therapy applications. A
semi-flexible and magnetic materials was developed based on the mineralization of type I
collagen with iron oxide. Type I collagen was templated with poly-aspartic acid to promote
the deposition of iron oxide into the gap zone of collagen fibers. Transmission electron
micrographs showed the deposition of iron oxide in collagen fibers. The composite material
is a nanoworm for potential tumor therapy applications.
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CHAPTER TWO
Hydroxyapate Substituted by Transition Metals: Experiment and
Theory
2.1 Introduction
Hydroxyapatite (HA) is a commonly used bone grafting material and is a well-documented
biomaterial known for its osteoconductivity.[55, 85] The main mineral phase of bone is
HA, Ca10(PO4)6(OH)2, and its bioactivity can be modified through substitutions of other
anions, cations, or functional groups. Well studied and commonly found trace elements
in bone are Mg2+, Sr2+, CO32-, and SiO44-; these elements have been shown to render HA
more bioactive compared to stoichiometric HA.[86–89] The hexagonal crystal structure
of HA allows for a wide variety of substitutions that can alter bioactivity but also physical
properties as well.[90] Other possible substituents which are less studied are transition
metals of the 3d block which are necessary for normal biological function.[91, 92]
One unique characteristic of some transition metals is their magnetic response, one that
can be modified and tuned in HA, which is diamagnetic, via substitutions. Thus, through
substituting with magnetic ions HA with magnetic properties can be achieved resulting in a
biocompatible and magnetic biomaterial. There is a wide range of biomedical applications
for biocompatible and magnetic materials such as drug delivery, cell separation, magnetic
resonance imaging, and hyperthermia applications.[31, 93–95] Iron oxide nanoparticles are
currently used for these applications but there have been concerns over acute toxicity.[47]
Since HA is biocompatible and biodegradable, application of magnetic HA will mitigate
these concerns.
The most commonly used metal for imparting HA with magnetic properties is iron.[60,
63–65] The choice of iron as a dopant stems from its high daily dietary need and its large
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magnetic moment. Other transition metals possess the potential and have rendered HA
magnetic, such as cobalt [96], but concerns over toxicity has limited the research despite the
fact that cobalt is required in trace amounts for vitamin B12 function.[97] Another suitable
transition metal that has received little attention is manganese, which has been shown
to influence bone remodeling and is used as a supplement to retard bone loss.[98, 99]
However, initial studies have reported that manganese substitution does not affect the
magnetic properties of HA.[62] Many elements have the potential to yield magnetic HA
with varying levels of bioactivity and magnetization.
The time to synthesize and characterize all possible magnetic HAs is laborious and time
consuming. The use of density functional theory (DFT) calculations to identify promising
new materials helps to guide and expedite experimental work. Computational efforts
coupled with experimental work has provided information on site preference, structural
modifications, and possible mechanisms of substitution in Pb, Cd, Sr, Mg, Zn, Ti, Si, CO32-,
and F.[66, 100–109] In Si substituted HA, DFT has been used to study defect chemistry
with results suggesting two different charge compensation mechanisms (1) the formation
of HSiO4 groups under hydrating conditions and (2) under dehydration the formation
of OH vacancies, again DFT results coincided well with experimental data.[106, 107]
Material property changes have been successfully predicted with DFT in calcium deficient
hydroxyapatite where Bhat et al. calculated a decrease of 30 % in elastic properties due
to calcium vacancies which coincided with observed experimental results.[110] Minor
differences in optical properties have also been calculated for the Ca10(PO4)6X2 system
where X is OH, F, Cl, or Br has been calculated with DFT and only minor differences in
optical properties were calculated.[111] Theoretical work on magnetic HA systems have
focused on the calculation of magnetic spectroscopic parameters for electron paramagnetic
resonance (EPR) and Mössbauer spectras.[112–115] Jiang et al. used DFT to analyze
electronic structure and compute magnetic spectroscopic parameters for electron paramag-
netic resonance (EPR) and Mössbauer spectras of Fe2+ and Fe3+ substituted HA.[112] The
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comparison of experimental spectrums with computed spectroscopic parameters allowed for
the assignment of site occupancy of Fe2+ and Fe3+ in the HA crystal lattice.[112] While EPR
studies combined with DFT calculations have also helped understand interactions between
nitrate and Mn2+ions and nitrate and carbonate ions in the HA lattice where the nitrate
ions are the paramagnetic center of interest.[113–115]
Little theoretical work has been done on the magnetic properties of HA substituted
by divalent transition metals (MHA). Using DFT, we determined the most promising
transition metals that would yield the highest magnetic moment, followed by synthesis of
the substituted HAs. Herein we investigate the substitution of divalent transition metal
ions: Mn2+, Fe2+, and Co2+ in HA from both theoretical and experimental approaches.
2.2 Materials and Methods
2.2.1 Materials
Ammonium phosphate dibasic (99+%), iron chloride tetrahydrate (99+%), cobalt
chloride hexahydrate (analysis grade), sulfuric acid (95-98%), and potassium bromide (IR
grade) were purchased from Acros Organics. Calcium nitrate (99+%), manganese chloride
tetrahydrate (99+%), lanthanum chloride heptahydrate (99+%), nitric acid (69.2%), and
ammonium hydroxide (29.45%) were purchased from Fisher Scientific.
2.2.2 HA and MHA synthesis
HA was synthesized via a wet chemical method. An aqueous solution of ammonium
phosphate dibasic (80 mM) was added drop-wise to an aqueous calcium nitrate solution
(225 mM) at room temperature with the calcium to phosphate ratio maintained at 1.667.
Ammonium hydroxide was used to raise the pH of both solutions above 11 prior to mixing
the two solutions. Once the two solutions were completely mixed, the temperature was
raised to 95 ◦C and maintained at the temperature for five hours. Then the solution was
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cooled to room temperature and aged for two days under constant stirring. The precipitates
were collected via centrifugation and washed 3 times with de-ionized, 2 times with ethanol
and vacuum dried.
MHA samples were fabricated through an ion-exchange procedure. A salt solution of
the desired transition metal (MnCl2, FeCl2, or CoCl2) was prepared at a concentration of
0.02 M, and the pH of the solution was adjusted to 2.7 with dilute sulfuric acid. Previously
synthesized HA was immersed in the ion-exchange solution at 0.5 g/dL and sonicated
for one hour at room temperature with intermittent stirring. The ion-exchanged HA was
collected by centrifugation, washed 3 times with DIW, and vacuum dried.
2.2.3 Characterization
Chemical analysis of the calcium and transition metal was determined by atomic absorp-
tion spectroscopy (Perkin Elmer Atomic Adsorption Spectrometer 3100). In brief, 15 mg of
MHA powder was dissolved in 200 µL of concentrated nitric acid (15.9 M). A 2 M nitric
acid solution with 5% (w/v) lanthanum chloride was then used to raise the total volume to
1 mL. The total volume was diluted to 20 mL with 0.1 M nitric acid and dilutions of the
solution were used for chemical analysis.
FTIR spectra were acquired on a Nicolet Magna 560 FTIR spectrometer. Specimens were
prepared using the potassium bromide method. In brief, powder samples were diluted to
one part per million in KBr, grinded into a fine powder and then pressed into a transparent
pellet. The FTIR spectra were acquired over the range of 4000-400 cm-1 with a resolution
of 4 cm-1 and a total of 32 scans.
Powder x-ray diffraction (XRD) patterns were acquired with a Bruker D2 phaser X-ray
diffractometer operating at 30 kV and 10 mA using Cu Kα radiation. Diffraction patterns
were collected over 2θ between 10-120◦ with a step size of 0.01◦ and a scan rate of 4s per
step. Powder patterns were refined using the Rietveld method with the general structural
analysis system (GSAS) and the EXPGUI interface.[116, 117]
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In order to assess the surface composition and oxidation state of the transition metal
dopant, X-ray photoelectron spectroscopy (XPS) was employed using a VG X-ray Photoelec-
tron Spectrometer with an Al Kα radiation source. High resolution XPS spectrums were
acquired of the transition metal 2p and O 1s peaks using a pass energy of 50 eV and a step
size of 0.1 eV. Spectrums were calibrated by setting the adventitious carbon peak to 284.7
eV, and CasaXPS was used to deconvolute the spectra.
Magnetic measurements were performed using a vibrating sample magnetometer (VSM)
attached to the evercool physical property measurement system (from Quantum Design).
Magnetization measurements were carried out at room temperature and with applied DC
magnetic fields of up to 1 tesla.
2.2.4 Theoretical Calculations
Our DFT calculations were performed with the Vienna ab initio simulation package
(VASP), [118] using the Perdew-Burke-Ernzerhof (PBE) [119] generalized gradient approx-
imation (GGA) and a plane wave energy cutoff of 750 eV. Dense Monkhorst-Pack k-point
meshes [120] of 2 x 2 x 2 were used for sampling the Brillouin zone of HA. All atoms were
allowed to relax to their equilibrium positions until atomic forces are smaller than 0.01 eV /
Å.
2.3 Hydroxyapatite Crystal Structure
HA occurs in a hexagonal crystal structure (space group P63/m) with 44 atoms per unit
cell and lattice parameters a = b 6= c and α = β = 90◦, γ = 120◦. The unit cell and the
local environment of Ca in pure HA is depicted in Figure 2.1. There are two distinct Ca
sites where cation exchange may occur. The Ca(1) site is surrounded by nine oxygen ions
from the surrounding phosphate tetrahedron and forms a distinct Ca channel parallel to the
c-axis. The Ca(2) site is surrounded by six oxygen ions from five phosphate groups and the
hydroxyl ion. The Ca(2) ions form triangular bases staggered by 60◦ above and below the
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OH ion. The OH ion similar to Ca(1) forms a distinct channel parallel to the c-axis. Based
on the distance and the coordination number of oxygen and calcium, three oxygen atoms
are defined as O(1), O(2) and O(3). The oxygen in OH- is defined as OH. Thus the formula
for HA can also be written as Ca(I)4Ca(II)6(PO(1)O(2)O(3)2)6(OHH)2.
Figure 2.1: On the left is the unit cell of hydroxyapatite from the calculated atomic
positions. To the right of the unit cell is distribution of the local environment of Ca in
pure HA and Fe in FeHA. Bond distances are in Å.
The theoretical lattice constants from DFT calculation are a = b = 9.55 Å and c = 6.94
Å, which are in good agreement with the previously reported experimental values of HA: a
= b = 9.43 Å, and c = 6.88 Å.[121] We also compare atomic positions and relaxed bond
lengths in the unit cell with experimental and past DFT results for undoped HA in Table 2.1
and Table 2.2. Our results are very close to the experimental data.[122] Based on Figure
2.1, we note that there are six nearest neighboring oxygen atoms and three second nearest
adjacent oxygen atoms for Ca(1), while Ca(2) has six nearest neighboring oxygen atoms
and only one second nearest adjacent oxygen atom.
2.4 Results and Discussion
The phase purity of the as-synthesized HA and MHA was evaluated using X-ray diffrac-
tion. Powder diffraction patterns of these samples are depicted in Figure 2.2 along with
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Table 2.1: Calculated atomic fractional coordinates of HA compared to literature values
Atom
This Work Other DFTa Expb
x y z x y z x y z
Ca(1) 0.333 0.667 0.004 0.333 0.667 0.003 0.333 0.667 0.001
Ca(2) 0.251 0.999 0.256 0.251 1 0.25 0.246 0.993 0.25
P 0.399 0.369 0.248 0.400 0.369 0.252 0.400 0.369 0.25
O(1) 0.332 0.486 0.251 0.333 0.487 0.253 0.329 0.484 0.25
O(2) 0.588 0.464 0.245 0.588 0.463 0.247 0.589 0.466 0.25
O(3) 0.34 0.257 0.068 0.338 0.256 0.073 0.348 0.259 0.073
OH 0 0 0.246 0 0 0.285 0 0 0.25
aRef[123], bRef[121]
Table 2.2: Calculated bond lengths (Å) and bond angles (◦) for HA compared to literature
values
This Work Other DFTa Expb
Bond length
P-O(1) 1.550 1.541 1.533
P-O(2) 1.563 1.554 1.544
P-O(3) 1.551 1.545 1.514
Ca(1)-O(1) 2.437 2.425 2.416
Ca(1)-O(2) 2.477 2.469 2.449
Ca(1)-O(3) 2.817 2.827 2.802
Ca(2)-O(1) 2.818 2.798 2.712
Ca(2)-O(2) 2.366 2.357 2.356
Ca(2)-O(3) 2.391 2.367 2.367
Bond angles
O(1)-P-O(2) 111
O(1)-P-O(3) 11.8
O(3)-P-O(2) 107.9
O(1)-Ca(2)-O(2) 47.3
O(1)-Ca(1)-O(2) 28.5
aRef[123], bRef[121]
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Table 2.3: Calculated lattice parameters of HA and MHA for site(1) and site(2) substitu-
tions. Experimental lattice parameters were obtained from Rietveld refinements. Units
(Å)
System Lattice Constant Site(1) Site(2) Exp
HA
a 9.55 - 9.4220(1)
c 6.94 - 6.8867(8)
MnHA
a 9.32 9.47 9.4205(1)
c 6.81 6.9 6.8805(9)
FeHA
a 9.52 9.38 9.4212(3)
c 6.85 6.95 6.8841(2)
CoHA
a 9.50 9.52 9.4197(2)
c 6.85 6.94 6.8820(1)
the computed XRD patterns from the theoretical model, Figure 2.3. The as-synthesized
HA is identified with JCPDF 09-432 and the substituted HA do not exhibit any extraneous
peaks, suggesting a single phase in all the powders. Rietveld refinements were performed
on the synthesized powders using the refined atomic positions reported by Veselinovic
et al.[124] The refined lattice parameters of HA and MHA are summarized in Table 2.3,
which are in good agreement with the calculated values from DFT assuming a 10 atomic
percent substitution. The small differences in peak position between experimental and
theoretical diffraction patterns arises from the differences in the calculated and observed
lattice parameters. Energy dispersive X-ray spectroscopy was used to assess the stoichiom-
etry of MHA the (Ca+M2+)/P ratios were 1.72, 1.71, and 1.69 for MnHA, FeHA, and
CoHA respectively which is in good agreement with the theoretical Ca/P ratio of 1.66.
From atomic absorption spectroscopy, the M2+/Ca ratios were determined to be 0.07, 0.12,
and 0.05 for MnHA, FeHA, and CoHA, respectively. Changes in lattice parameters due to
substitution are typically a function of the substituent percentage. Since the transition
metal percentage was not controlled, it is difficult to directly compare the effect between
transition metals on the lattice parameters.
Chemical analysis indicates that the transition metals successfully replaced calcium in the
HA lattice. Between the two distinct calcium sites DFT calculations indicate that the Ca(II)
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Figure 2.2: Powder XRD patterns of the synthesized HA and M2+HA. HA (a), MnHA (b),
FeHA (c), and CoHA (d).
site is the most energetically favorable site for substitution. Experimentally site occupancies
cannot reliably be determined since diffraction data was not collected using synchrotron
X-rays or with neutron diffraction. Previous experimental and theoretical studies of Sr, Pb,
and Cd substituted HA systems utilizing synchrotron radiation have shown that DFT does
accurately predict the most energetically favorable site occupancy.[66, 100, 101]
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Figure 2.3: Calculated XRD patterns from DFT calculations of HA and M2+HA: HA (a),
MnHA (b), FeHA (c) and CoHA (d).
To further understand the effect of transition metals on the structure of hydroxyapatite,
DFT calculations were performed on the Ca9M(PO4)6(OH)2 (MHA) systems. Since the
valence state of Ca2+ and M2+ are the same, charge compensation defects were not con-
sidered for M2+ substitution at the Ca(I) or Ca(II) sites. Table 2.3 displays the calculated
lattice parameters of the MHA, which are in good agreement with data obtained from
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experiment. The contraction in the lattice parameters of MHA are attributed to the smaller
ionic radius and the more electronegative character of Mn2+, Fe2+, and Co2+ compared to
Ca2+. These differences result in small structural distortions which is seen in the analysis of
the interatomic distances of FeHA, shown in Figure 2.1. The observed decrease of the bond
length between the Fe and the first neighboring oxygen atoms results from iron being more
electronegative than calcium attracting the oxygen atoms closer. The Fe at the Ca(2) results
in one broke bond with oxygen, where the O(1) bond is broken.
The FTIR spectra of the pure and substituted HA are displayed in Figure 2.4 along with
the corresponding spectra computed using DFT. It can be seen that both results are in
good agreement, indicating that the nearest neighbor environments and bond strengths are
correctly captured in the DFT computations. There is a difference between the computed
and experimental spectra. The error between the experimental and theoretical spectra for
HA, MnHA, FeHA, CoHA, are 3.4 %, 3.3 %, 3.8 %, and 4.1 %, respectively. Overall, the
theoretical and experimental spectra are in good agreement. Bhat et al. observed error
ranging from 2 % to 8 % between theoretical and experimental spectra for stoichiometric
HA.[110] Also, the theoretical model of a perfect crystal does not take into account defects
such as vacancies that are often present in real samples. Bhat et al. calculated the IR spectra
of calcium deficient HA and observed a shift in the vibrational modes of phosphate to lower
wavenumbers.[110] The MHA spectra display typical vibrational modes of HA, indicating
successful substitution of M2+ into the HA lattice. The vibrational modes of phosphate are
observed around 1040 and 1095 cm-1 corresponding to the v3 mode, and the v4, v1, and
v2 modes are present around 570, 600, and 480 cm-1, respectively. The vibrational and
liberation absorption bands for OH- are observed around 3550 and 640 cm-1, respectively,
which are not predicted in the theoretical spectra. Other absorption bands observed in the
experimental spectra that are not predicted by theory are the absorption bands observed
at 1450, 1410, and 865 cm-1, which correspond to the v3 and out of plane v2 mode for
CO32-. The presence of the CO32- bands is a result of the HA synthesis procedure at ambient
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atmosphere. Carbonated HA is formed from the adsorption of CO2 from the ambient
atmosphere. From the position of the CO32- bands the substitution of CO32- is predominately
at the phosphate site.
High resolution XPS spectra of the substituted transition metal in MHA, as shown in
Figure 2.5 (a, c, e) and tabulated in Table IV, displays two peaks which are attributed to
the 2p3/2 and 2p1/2 states from spin-orbit splitting.[125] For MnHA the peaks at 643.4 and
654.6 eV are the 2p3/2 and 2p1/2 peak pairs from the spin-orbit splitting, which corresponds
with the Mn2+ substituted for Ca in the HA lattice.[126] The peaks at 648.0 and 658.8 eV
are also 2p peak pairs, but are shakeup satellites of Mn2+. In the case of CoHA the 2p peak
pair at 781.1 and 797.1 eV corresponds to Co2+ substituted in either Ca site in the HA lattice
and the 2p peak pair at 786.5 and 801.9 eV are from shakeup satellites. The strong nature of
the shakeup satellite is characteristic of Co2+ with paramagnetic properties.[127] The peaks
at 711.1 and 720.1 eV in the FeHA spectra are the 2p peak pairs from spin-orbit splitting
characteristic of Fe2+PO4 bonding, which corresponds to Fe2+HA in the lattice.[128] The
2p peak pair around 715.4 and 724.5 eV can be attributed to iron residing on surface sites,
which requires more energy to create a photoelectron.[128] The last peak pair around
720.1 and 731.9 eV is a shakeup satellite of iron. The O 1s spectra were also acquired and
all MHA displayed peaks around 528, 530, 531, and 533 eV. It should be noted that the
peak at 531 eV is characteristic of O in HA (NIST database) and the peak around 530 eV
is characteristic of surface carbonate (NIST database). The peak at 533 eV is typical of
bridging oxygen’s. The peak at 528 eV can be attributed to C-O bonding from the carbon
tape used for mounting powders. No recognizable metal oxide bonding was identified in
the transition metal 2p or O 1s spectra. All the paramagnetic transition metals appear to
have successfully incorporated into the HA lattice in a divalent state.
XPS is successful at probing the electronic structure through core level electrons but
does not provide information about interactions in the valance band. To address this point,
we calculated the band structure and density of states, shown in Figure 2.6, using DFT to
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Figure 2.4: FTIR spectra of the synthesized HA and M2+HA. HA (a), MnHA (b), FeHA
(c), and CoHA (d).
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Figure 2.5: XPS spectra of M 2p (left) and O 1s (right) peaks. MnHA (a, b), FeHA (c, d)
and CoHA (e, f).
further understand the effect of transition metals on the electronic properties of HA. The
valance band maximum of HA is set as 0 eV in all figures, and the calculated PBE band gap
of pure HA is 5.09 eV which is consistent with the previously computed result of 5.30 eV
from Matsunaga et al.[129]
When the transition metals are substituted into HA, the band gap of the MHA decreases
compared to pure HA as shown in Figure 2.6 and Table 2.5. In order to describe the
influence of specific atoms on the electronic structure of HA, density of states (DOS) and
projected density of states analysis were performed, as shown in Figure 2.6. Comparing to
the partial DOS of pure HA, new energy states of ion-substituted HA are introduced at the
top of the valence band owing to the interaction between 2p states of O and the 3d energy
states of Fe, Co, and Mn. The interaction between these states results in decreasing the
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Table 2.4: Peak positions from deconvoluted MHA transition metal (M) 2p spectra in eV.
M
2p3/2 2p1/2
MnHA 643.4 648.0 654.6 658.8
FeHA 711.1 715.4 720.1 724.5 728.3 731.9
CoHA 781.8 786.5 797.1 801.9
Table 2.5: Band gap of MHA, given in eV. The data in parenthesis is experimental results
from literature
System Site(1) Site(2)
HA 5.09 (5.3a)
MnHA 4.29 3.3
FeHA 4.15 3.8
CoHA 4.29 4.36
aRef[129]
band gap in MHA.
Also, when Fe or Mn is substituted at the Ca(2) site, the band gap is smaller than
substitution at the Ca(1) site. The structural distortion from Fe, Mn, and Co at site (1) is
less compared to site (2) substitution. The coordination number of Fe, Mn, and Co at site
(1) is the same as that of Ca(1), which is 9. Small variations of structure leads to extension
of the band tail. However, the interaction between Fe (or Mn) at site (2) and the OH ion
lead to the rotation of the OH ion, which results in the production of discrete states in the
band structure of HA.
Magnetization measurements depicted in Figure 2.7 show that all the substituents
induced a transition from diamagnetic behavior, which is characteristic of HA, to a super-
paramagnetic behavior. A small ferromagnetic signal is observed at low magnetic fields
followed by a strong paramagnetic response at high fields. The observed superparamag-
netic response may be due to M2+ residing in Ca(2) sites or surface effects as previously
discussed.[65] In brief, as the surface to volume ratio increases, a larger number of atoms
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Figure 2.6: Projected density of states for M2+HA.
reside on the surface possibly resulting in dangling bonds, a change in coordination and
surface disorder, which can lead to an increase in their magnetization values.[130] The
transition from diamagnetic to paramagnetic response is in agreement with the theoretical
calculations. For a 10 percent substitution on the Ca-site, our theoretical modelling predicts
magnetic moments of 5, 4 and 3 Bohr magnetons for MnHA, FeHA, and CoHA, respectively.
Since the MHA fabricated by different approaches have varying levels of M2+ substituted
into the lattice, magnetization curves were normalized to the molar amount of M2+ per
MHA. In agreement with the calculations, MnHA displayed the highest magnetization value
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of 100 emu/mol M2+ at 10 kOe (or 1 tesla) of all the substituents, while FeHA and CoHA
had similar magnetization values around 65 emu/mol M2+. Qualitatively, the slope of the
high field magnetization data is also indicative of the magnitude of the magnetic moment
and the observed slopes are MnHA > FeHA > CoHA, which is in good agreement with the
theoretical calculations.
Figure 2.7: Mass magnetization of MnHA, FeHA, and CoHA normalized to the transition
metal content.
2.5 Conclusion
Manganese, iron and cobalt were successfully substituted into hydroxyapatite (HA) and
the observed crystal structure, FTIR spectra, electronic and magnetic properties were in
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good agreement with DFT calculations. The presence of transition metals in a +2 oxidation
state was confirmed by XPS; FTIR and XRD identified the MHA without any detectable
impurity phases. Incorporation of magnetic ions into the HA lattice was sufficient to induce
a transition from the diamagnetic behavior (for pure HA) to a paramagnetic one, with the
observed magnetization values in the order of MnHA >FeHA >CoHA.
The results from DFT calculations were in good agreement with experimental data. Thus,
the DFT calculation could be a useful tool for predicting physical and magnetic properties of
different ion-substituted hydroxyapatite powders, and such a tool can guide future studies
on the synthesis of ion-substituted hydroxyapatite with desired properties.
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CHAPTER THREE
Synthesis and Characterizaiton of Iron-Substituted Hydroxyapatite
3.1 Introduction
Magnetic nanoparticles (NPs) have enticed significant interest as theranostic agents.[1–
7] owing to the ability of an external magnetic field to non-invasively penetrate tissue
allowing potential ‘remote’ control over the particles. Remote applications include: contrast
enhancement for magnetic resonance imaging, hyperthermia, cell stimulation, and targeted
drug delivery.[1, 2, 4, 7–10] Magnetic particles with superparamagnetic behavior are ideal
for the aforementioned applications. Superparamagnetic behavior is characterized by a
large magnetic moment in the presence of an applied magnetic field and a zero remanent
magnetic moment when the applied magnetic field is reduced to zero. This property allows
for ‘remote’ control over particles, and thus is ideal for in vivo applications.[2]
Iron oxides are commonly used for biomedical applications, since nanoparticles of
iron oxide synthesized below 30 nm render the particles superparamagnetic due to small
size effects.[131–133] Along with lucrative magnetic properties, the small size of these
particles can avoid the body’s system of macrophages, the reticuloendothelial system (RES),
which clears foreign debris prolonging blood circulation time.[134] However, adsorption
of proteins from blood plasma will reduce the NPs circulation time. To improve the
blood circulation time, surface functionalization with polyethylene glycol is performed to
prevent protein adsorption.[135–138] Despite iron being a daily elemental need, the poor
biodegradation and acute toxicity[47] have raised concerns over the application of iron
oxides to medical applications.
To circumvent the issue of biodegradation and acute toxicity concerns, a few research
groups have focused on doping biocompatible materials with magnetic ions to impart
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magnetic properties.[60–63, 139] An ideal material for this approach is hydroxyapatite
(HA), (Ca10(PO4)6(OH)2), the mineral phase of bone, which due to its unique structure
allows for a wide array of substitutions. The structure of HA, space group P63/m, allows
for substitution of the calcium sites by divalent or trivalent cations and the hydroxyl site
by other anions. In the structure of HA, calcium occupies two distinct sites: (i) the Ca(II)
site forms triangles staggered by 60° around the hydroxyl channel, while (ii) the Ca(I) site
forms a channel surrounded by phosphates. Substitution of the calcium site with metal ions
such as strontium have exhibited enhanced bioactivity, while substitution of the hydroxyl
site with fluorine leads to improved crystallinity and thermal stability.[140, 141]
In regards to magnetic impurities, iron substitution has been shown to induce an intrinsic
paramagnetism in HA along with maintaining biocompatibility.[60–62] Iron substituted HA
(FeHA) has been synthesized via multiple approaches: hydrothermal, co-precipitation, and
ion exchange.[60, 63] The iron source is typically a salt of Fe2+ or Fe3+; different groups
have noted paramagnetic or superparamangetic properties of HA from iron substitution
depending upon the oxidation state of iron.[60, 63] For example, Panseri et al. observed
superparamagnetic properties in FeHA prepared by a neutralization wet synthesis method
that resulted in FeHA with a minimal amount of iron oxide produced as a second phase.[60]
An alternative approach to co-precipitation is cation exchange, in which immersion of
an ionic material into an aqueous solution results in the replacement of a cation within
the crystal lattice with a cation from the solution. Cation exchange is easily accomplished
at room temperature and within a short time scale. Herein we report a facile approach
utilizing cation exchange to manipulate the magnetic properties of FeHA. Its magnetic
properties varied from paramagnetic to superparamagnetic and was dependent upon the
oxidation state of iron and the particle size of FeHA samples.
36
3.2 Materials and Methods
3.2.1 Materials
The following materials were purchased from Acros Organics with a purity greater
than 99%: iron chloride tetrahydrate, o-phenanthroline, hydroxylamine hydrochloride,
ammonium phosphate dibasic, iron chloride hexahydrate (97+%), and potassium bromide
(IR grade). Calcium nitrate tetrahydrate (99+%) , ammonium hydroxide (29.45%), sodium
acetate (99+%) and glacial acetic acid were purchased from Fisher Scientific.
3.2.2 HA and FeHA synthesis
HA was synthesized via a wet chemical method. In this method, an aqueous solution of
ammonium phosphate dibasic was added drop-wise to an aqueous calcium nitrate solution
with the calcium to phosphate ratio maintained at 1.667. Then the solution was heated
to 95 °C for five hours and cooled to room temperature. After two days of ageing, the
precipitates were collected via centrifugation and washed three times with de-ionized
water (DIW). FeHA was fabricated via a cation exchange method. For this, previously
synthesized HA powder was immersed in an iron salt solution and sonicated for one hour.
The iron salt solutions were composed of FeCl2 (Fe2+HA), FeCl3 (Fe3+HA), and FeCl2 with
and equal amount of FeCl3 (Fe2+3+HA); all solutions had a total iron concentration of 0.02
M. Substituted hydroxyapatite powders were collected via centrifugation and rinsed three
times with DIW.
3.2.3 Characterization
Particle size and morphology were characterized with a JEOL 6330F field emission scan-
ning electron microscope (FESEM) equipped with an energy dispersive X-ray spectroscopy
(EDXS) which was used to verify the presence of iron and to determine the (Fe+Ca)/P ratio.
EDXS analysis was performed on four randomly selected areas of HA and FeHA powders.
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The atomic percentages were quantified through a semi-quantitative method and the results
of the four areas were averaged together. The phase purity of HA and iron substituted HA
was examined by X-ray diffraction (XRD) with a Bruker D2 Phaser X-ray diffractometer and
a copper target. Scans were collected over 2-θ range of 10-70° with a step size of 0.02° and
a scan rate of one second per step. Small-range XRD patterns of the (002) and (211) peaks
were acquired over a 2-θ range 25-27° and 31-33°.
Fourier transform infrared spectroscopy (FTIR) was used to determine the functional
groups present in the samples. FTIR spectra were obtained with a Nicoltet Magna 560 FTIR
spectrometer; the potassium bromide method for pellets was used for specimen preparation.
Powder samples were diluted to 0.1 weight percent in KBr and grinded into a fine powder.
The powder mixture was pressed into a transparent pellet and FTIR spectra were acquired
over the range of 4000 to 400 cm-1.
The pH change of the iron salt solution during ion exchange was recorded using a pH
meter (Accumet Excel XL15). The pH value of the solution was measured every minute,
and the pH profile versus time was plotted for each ion exchange. The start of ion-exchange
occurs when HA powder is added to the ion exchange solution, which corresponded to time
zero. A HA control was performed, where the pH of DIW was adjusted to 2.2 with 1 N HCl
and the HA powder was immersed in the pH adjusted DIW and sonicated for one hour. The
pH profiles were recorded during the sonication process.
Iron quantification in fabricated powders was determined via a colorimetric assay.[142]
In brief, iron was extracted by dissolution with dilute hydrochloric acid. Then any ferric iron
was reduced to ferrous iron with a 10 % (w/v) solution of hydroxylamine hydrochloride.
The solution was then buffered to a pH of 4 with a 0.5 M acetate buffer. Any iron in solution
was converted to a vibrant red color with the addition of a 0.3 % (w/v) o-phenanthroline
solution. The absorbance of the solution was measured at 510 nm. In order to assess the
nature of iron bonding, X-ray photoelectron spectroscopy (XPS) was employed using a
VG X-ray Photoelectron Spectrometer with Mg Kα radiation source. High resolution XPS
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spectrums of the Fe 2p and O 1s peaks were acquired over the range of 705-735 and
525-540 eV. To account for sample charging, spectrums were calibrated by setting the
adventitious carbon peak to 284.5 eV. De-convolution of high resolution XPS spectrums was
performed with the CasaXPS software.
The magnetization of the FeHA were determined using a vibrating sample magnetometer
(VSM) attached to the evercool physical property measurement system (from Quantum
Design). Magnetization measurements were carried out at 298 K and with applied DC
magnetic fields of up to one tesla.
3.3 Results and Discussion
3.3.1 Results
FESEM images of the as-synthesized HA and ion exchanged FeHA are displayed in Figure
3.1. HA particles displayed a spherical morphology with a particle size of approximately 49
nm, and ion exchanged particles displayed a spherical morphology with a slightly smaller
size than HA. Fe2+HA, Fe2+3+HA, and Fe3+HA have average sizes of 41, 46, and 47 nm,
respectively. A secondary morphology of small rods and aggregates were observed in all
samples. The presence of iron was verified from EDXS spectrums, as shown in Figure 3.2. A
significant iron peak is seen in the spectra for all FeHA samples and there is no observable
iron peak in the spectra for the as-synthesized HA. In contrast to Fe2+HA and Fe2+3+HA,
the Fe3+HA spectra displayed a significant peak from chloride.
X-ray diffraction patterns of all FeHA are shown in Figure 3.3. The as-synthesized HA
was identified with JCPDF 09-432, and FeHA powders did not exhibit any extraneous peaks.
All peaks are broadened and the intensities are attenuated in all three FeHA powders. The
most significant attenuation and broadening occurred in Fe3+HA. A shift to larger Bragg
angles was observed for the (002) plane for all FeHA powders. The peak shift for the (211)
plane largely depended upon the oxidation state of iron. The peak was shifted to a lower
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Figure 3.1: FESEM images of particle morphology for HA (a), Fe2+HA (b), Fe2+3+HA
(c), Fe3+HA (d).
Bragg angle for Fe3+HA and a higher Bragg angle for Fe2+HA, while Fe2+3+HA exhibited no
observable shift.
The FTIR spectrum of the as-synthesized HA and FeHA are displayed in Figure 3.4. The
HA spectrum displayed vibrational modes at 1030 and 1095 cm-1 corresponding to the v3
mode of phosphate. The v4 and v1 modes of phosphate were present at 563 and 602 cm-1,
respectively. The absorption band at 3550 and 625 cm-1 arise from the vibrational mode
and liberation of the hydroxyl group. The as-synthesized HA was partially carbonated with
absorption bands for the v3 mode and out of plane v2 mode for CO32- observed at 1450,
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Figure 3.2: Representative EDXS spectra of HA (a), Fe2+HA (b), Fe2+3+HA (c), Fe3+HA
(d).
1410 and 865 cm-1, respectively. All FeHA powders displayed the same absorption bands
as HA. A noticeable attenuation in the CO32- and an increase in the v2 absorption band
of water around 1625 cm-1 were observed for FeHA fabricated with a Fe3+ salt. Also, the
hydroxyl band at 3550 cm-1 was reduced to a shoulder in the water band for Fe3+HA and
was attenuated in other samples fabricated with a Fe3+ salt source.
The observed pH profiles of the ion-exchange process are depicted in Figure 3.5. A rapid
rise in pH was observed at the time corresponding to the addition of HA powder to the
solution. The pH value peaked within five minutes followed by a gradual decline. Fe2+3+HA
had the largest change in pH going from 2.3 to 4.3 followed by Fe3+HA (1.8 to 3.7) and
Fe2+HA (3.0 to 4.5). These changes in pH are less than the observed pH change in the HA
control where the pH changed from 2.2 to 5.0.
41
Figure 3.3: Top: powder XRD patterns of HA and FeHA powders. Bottom left: XRD
pattern of the (002) peak. Bottom right: XRD pattern of the (211) peak. HA (a), Fe2+HA
(b), Fe3+HA (c), and Fe2+3+HA (d).
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Figure 3.4: Top: FTIR spectrum of HA and FeHA powders. Bottom left: observed
attenuation of the hydroxyl band in FeHA specimens with Fe3+. Bottom right: reduction
in the carbonate bands and increase in the water band for FeHA specimens with Fe3+.
HA (a), Fe2+HA (b), Fe3+HA (c), and Fe2+3+HA (d).
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Figure 3.5: pH profile of the ion exchange process. HA (a), Fe2+HA (b), Fe2+3+HA (c),
and Fe3+HA (d). Time zero corresponds to the addition of HA to the solution. HA in DIW
with a pH of 2.2 was used as a control.
The total iron content in each specimen was first assessed with EDXS and XPS to
determine the bulk and surface (Ca+Fe)/P ratios as shown in Table 3.1, followed by
analysis with a colorimetric assay. The (Ca+Fe)/P for HA (1.66), Fe2+HA (1.65), and
Fe2+3+HA (1.63) are in good agreement with the stoichiometric Ca/P ratio of 1.67, while
Fe3+HA displayed a non-stoichiometric ratio of 1.36. In contrast, XPS analysis displayed
non-stoichiometric (Ca+Fe)/P ratios: 1.39 (Fe2+HA), 1.25 (Fe2+3+HA), and 1.04 (Fe3+HA)
for all three powders studied. Quantification of the total iron content showed that Fe3+HA
had the most iron at 11.9 wt% followed by Fe2+3+HA, 9.9 wt%, and Fe2+HA, 4.5 wt%.
High resolution spectra of the iron peak, Figure 3.6 (a,c,e), displayed two peaks around
711-713 eV and 724-726 eV, which are attributed to Fe 2p3/2 and Fe 2p1/2, respectively.
The Fe 2p peaks were resolved into two peaks. The main peaks for Fe 2p3/2 were observed
around 712 and 717 eV for Fe2+HA, 710.5 and 714 eV for Fe2+3+HA, and 713 and 718 eV
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Table 3.1: Fe+Ca/P ratio determined by EDXS and XPS
Fe+Ca/P Fe/Ca
EDXS XPS EDXS XPS
HA 1.66 – – –
Fe2+HA 1.65 1.394 0.115 0.277
Fe2+3+HA 1.63 1.043 0.439 0.473
Fe3+HA 1.36 1.252 0.952 0.762
Table 3.2: Peak positions of deconvoluted Fe 2p and O 1s spectras in eV.
Fe 2p3/2 Fe 2p1/2 O 1s
Fe2+HA 712.2 717.8 725.2 730.7 528.6 530.7 531.1 532.9
Fe2+3+HA 710.5 714 723.7 725 528.4 530.9 531.7 533.1
Fe3+HA 713.2 718 726.5 730.8 529.5 531.2 532.2 533.8
for Fe3+HA. High resolution spectra of O 1s peak were also aquired, as shown in Figure 3.6
(b,d,f), with one peak observed around 531.6-531.9 eV. The O 1s peak was deconvluted
into 4 peaks with the main peak observed around 531 eV for all FeHA. The second major
peak was observed around 530 eV in Fe2+HA and Fe2+3+HA, while it was observed around
532 eV in Fe3+HA. All the peak positions determined from the deconvolution of the spectra
are listed in Table 3.2.
Magnetic properties were affected by iron oxidation state and particle size, as illustrated
in Figure 3.7. Fe3+ substitution resulted in paramagnetism as seen in magnetic data of
Fe3+HA., while Fe2+ resulted in superparamagnetism as observed in magnetic data of
Fe2+HA. The combination of Fe2+ and Fe3+ resulted in superparamagnetic properties as it
was observed for Fe2+3+HA. The influences of particle size and shape on magnetic properties
of the HA particles were also investigated. The HA synthesis procedure was modified to
produce HA with needle shape morphology and a particle size of 300 nm. Larger Fe2+3+HA
particles resulted in paramagnetism, which is in contrast to the superparamagnetism
observed in Fe2+3+HA with a more spherical morphology and particle size around 45 nm.
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Figure 3.6: High resolution XPS spectrum and deconvolution of Fe 2p (a, c, and e) and
O 1s (b, d, and f). Fe2+HA (a dn b), Fe2+3+HA (c and d), Fe3+ (e and f).
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Figure 3.7: Magnetization measurements of Fe2+HA (a), Fe2+3+HA with a needle like
morphology (b), Fe2+3+HA (c), and Fe3+HA (d).
3.3.2 Discussion
Utilizing the ion exchange property of HA we investigated the influence of the oxidation
state of iron precursors on the magnetic properties of FeHA. The substitution of iron did
not affect the particle morphology or size. The phase purity of HA was also maintained
post substitution as seen from the absence of extraneous peaks in the XRD patterns (Figure
3.3). The observed peak shifts are indicative of iron substitution into calcium sites due
to changes in the lattice parameter resulting from differences in ionic radii and vacancy
formation. Substitution of Fe2+ and Fe3+ resulted in a contraction of the c-axis as observed
from peak shifts to larger Bragg angles. The broadening and reduction in intensity is due to
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increased lattice strain from iron substitution, since the radii of Ca2+ is greater than Fe2+
and Fe3+. The formation of calcium vacancies is depicted in Figure 3.8 and discussed later.
FTIR spectra (Figure 3.4) of FeHA specimens displayed the observed vibrational modes
from the v1, v3 and v4 modes of phosphate, the OH mode and the v2 mode of carbonate as
observed in HA, further indicating successful substitution of iron. The as-synthesized HA
is partially carbonated due to CO2 adsorption from the atmosphere during the synthesis
process. Carbonate substitution can occur at either the PO43- or OH- site; these substitutions
are distinguished by absorption bands around 1540, 1460 and 878 cm-1 for OH- and 1455,
1420 and 871 cm-1 for PO43- substitutions. Absence of the absorption band around 1540
cm-1 suggests that the carbonate incorporation predominately resided at the PO43- sites. The
reduction in intensity of the carbonate band in specimens prepared with Fe3+ salt source is
attributed to the dissolution and precipitation process during ion exchange. During this
process Fe3+ bonds to the PO43-, as indicated by XPS in Figure 3.6 (e), and not carbonate.
The precipitation process results in exclusion of carbonate from a lack of reactivity with
Fe3+.
The cation exchange process can occur in two manners: (1) formation of a reaction
zone[143] with simultaneous dissolution and precipitation occurs and/or (2) cations (e.g.
Fe3+) adsorb to the surface and diffuse into the material with concurrent substituted cation
(e.g. Ca2+) release. For iron substitution the dominant mechanism is process (1), the acidic
condition of the iron solution induces partial dissolution of HA and the phosphate ions react
with iron[144] to introduce iron into the lattice. The partial dissolution of HA resulted in
a rapid rise in the pH of the solution from the release of OH- ions, which is observed in
the change of the pH profile upon the addition of HA powder. After the rapid rise in pH
the re-precipitation process resulted in a gradual decline in the pH as OH- and iron ions
have precipitated into FeHA. The amount of iron incorporated is related to the initial pH
of the solution. Lower pH values correspond to higher iron activity and a greater degree
of HA dissolution, which results in more iron substitution. The initial pH values were 1.8,
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2.3 and 3.0 for Fe3+, Fe2+3+, and Fe2+ solutions, respectively. As such, the amount of iron
substitution in HA followed the following order: Fe3+ is greater than Fe2+3+ which is greater
than Fe2+.
The incorporation of Fe3+ decreases the crystallinity of HA, which can be attributed
to the non-stoichiometric substitution of Fe3+ for Ca2+. The charge imbalance can be
compensated by a number of mechanisms (Figure 3.8): formation of calcium vacancies
(reaction (1)), deprotonation of the hydroxyl group (reaction (2)), or a combination of
calcium and hydroxyl vacancies (reaction (3)).
3Ca2+−→2Fe3+ + Ca2+vac (1)
Ca2+ +OH−−→Fe3+ +O2− (2)
2Ca2+ +OH−−→Fe3+ + Ca2+vac +OH−vac (3)
The non-stoichiometric (Fe+Ca)/P ratio observed from EDXS implies that mechanism (1)
and (3) are the most predominate. The reduction in the hydroxyl band intensity from
FTIR supports mechanisms (2) and (3). Like Fe3+, Fe2+ substitution also occurs through
a reaction zone, but Fe2+ has an initial pH of 3.0 compared to 1.8 for Fe3+. The less
acidic pH of Fe2+ reduces the degree of dissolution of HA resulting in a smaller reaction
zone for re-precipitation of FeHA. The size of the reaction zone limits the amount of iron
incorporated into HA. The smaller reaction zone resulted in less incorporation of Fe2+ into
HA compared to Fe3+. Compositional analysis from XPS shows a Fe/Ca ratio two times
larger than EDXS, which suggests that the substitution of Fe2+ adopts a core-shell like
structure with more Fe2+ near the surface indicating a small reaction zone. Fe2+ can easily
be oxidized to Fe3+ and this can occur in the HA lattice by (4):
Fe2+ +OH−−→Fe3+ +O2− (4)
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This effect would result in the formation a Fe2O3 phase, which has not been identified in
FeHA within the detection limits of the characterization techniques.
Figure 3.8: The mechanisms of charge compensation are depicted as viewed along the
c-axis of the HA unit cell. The HA unit cell is illustrated in (a) and charge compensation
mechanisms (1)-(3) in b-d.
The bonding nature of iron and oxygen in FeHA was investigated using XPS. The
observed binding energies for Fe3+HA and Fe2+HA are characteristic of FePO4 bonding,
which is typically observed between 711-714 eV and depends upon the valence state
and coordination environment of iron.[128, 145–147] Comparison of Fe2+HA to Fe3+HA
spectrum reveals that the binding energy for Fe3+HA is greater than the binding energy
for Fe2+HA; this is to be expected due to the larger positive charge on Fe3+ causing it to
bind tightly to the phosphate group. Deconvolution of Fe2+3+HA Fe 2p peak reveals binding
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energy characteristic of FePO4 bonding. The peak around 710.5 can be attributed to iron in
the HA lattice and the peak around 714 e V can be attributed to iron residing on surface
site which requires more energy to create a photoelectron.[128] The large value of the
full width at half maximum of these peaks does not allow for the distinction from the
contribution of Fe2+ or Fe3+ to the signal.
The main peak in the O 1s spectra around 531.6 eV is attributed to the oxygen in HA
where a peak is typically observed between 531.3-531.8 eV (NIST database). The peaks
observed around 530.9 and 528.6 eV are attributed to the presence of surface carbonate,
which is typically observed around 528.6 or 530.7 eV (NIST database). The observed peak
around 533.3 eV is from bridging oxygen of P-O-P bonding.[148] Through the combination
of the Fe 2p and O 1s spectra it appears iron has been incorporated into the HA lattice and
is bonded to phosphate groups without the presence of iron oxides.
Magnetization measurements revealed that iron substitution modified the magnetic
properties of HA (which is diamagnetic) based on the fabrication method.[63] As sown
in Figure 3.7, Fe3+HA sample displayed paramagnetism, while Fe2+HA and Fe2+3+HA
showed superparamagnetic behavior. As it can be seen in the figure, Fe2+3+HA showed
much higher magnetization as compared to Fe2+HA. The superparamagnetism observed
in both Fe2+HA and Fe2+3+HA requires the coupling of magnetic spins. Many groups
have observed coupling of magnetic spins in iron phosphate materials through observed
antiferromagnetic and ferromagnetic transitions.[149, 150] However, the absence of a
saturation magnetization in both Fe2+HA and Fe2+3+HA samples implies that the coupling is
of short-range order. The magnetic ordering in the present Fe2+HA and Fe2+3+HA is due to
super-exchange interactions, the magnetic coupling of two magnetic cations through a non-
magnetic anion, from Fe-OH-Fe and Fe-O-P-O-Fe bonding. Panseri et al. has also observed
superparamagnetism in Fe2+3+HA synthesized through a co-precipitation approach.[60]
In their work, the magnetic properties were largely attributed to a secondary iron oxide
phase and not the Fe2+3+HA phase. However, it was mentioned that not all of the observed
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magnetization could be attributed to the iron oxide phase some magnetization was from
Fe2+3+HA. It was also hypothesized that there is some type of magnetic ordering within
FeHA.[60] From a structural point of view, an iron ion can occupy either the Ca(I) or
Ca(II) site. Theoretical calculations have shown that the Ca(I) site is energetically favorable
for Fe3+ while occupancy of Ca(II) site is more favorable for Fe2+.[112] The Ca(II)-OH
distance is 2.35 Å, which should allow for super-exchange interactions between Fe2+ or
Fe3+ atoms on Ca(II) sites through Fe-OH-Fe bonding. While the Ca(I) site is coordinated
with O atoms from the surrounding phosphate groups with Ca(I)-O distances varying from
2.32 to 2.88 Å.[121] Super-exchange interactions for the Ca(I) site could occur through
Fe-O-P-O-Fe bonding albeit weaker compared to Ca(II) site. Occupation of Fe2+ in the Ca(II)
site may explain the superparamagnetic observed for present Fe2+HA and Fe2+3+HA. It
should be noted that previous attempts of Fe2+HA fabrication through ion exchange yielded
diamagnetic properties.[63]
Changing the particle size and shape of Fe2+3+HA from nanospheres to a needle like
morphology with a particle size of 300 nm resulted in a decrease in magnetization at
10 kOe and a transition to paramagnetic behavior. The increase in magnetization with
smaller size particles can be attributed to surface effects. As the surface area to volume
ratio increases, a larger percent of atoms reside on the surface. In nanomaterials surface
effects, such as dangling bonds, change in coordination and surface disorder can cause a
change in magnetic behavior when compared to the bulk material, and these effects can
increase magnetization to larger value than the bulk magnetization.[130] Similar effects
have been observed in iron oxides nanoparticles of varying shapes where spheres have
larger magnetization than rods, and the effect of shape on magnetic properties has been
related back to surface effects such as missing atoms.[151]
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3.4 Conclusion
Iron substituted hydroxyapatite (FeHA) has been fabricated through a facile ion-exchange
method without the detection of a secondary impurity phase. The magnetic properties
of such samples are found to be dependent upon the oxidation state of iron and particle
size. The presence of Fe2+ resulted in a superparamagnetic response and an even larger
magnetization with a superparamagnetic response was observed when both Fe2+ and Fe3+
were present. The magnetization of Fe3+HA at 10 kOe is comparable to the magnetization
observed in Fe2+3+HA at 10 kOe. We hypothesize that these unique magnetic properties
arise from the exchange interactions.
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CHAPTER FOUR
A Comparative Study of the Sintering Behavior of Pure and
Manganese-Substituted Hydroxyapatite
4.1 Introduction
Hydroxyapatite (HA) is an inorganic constituent of natural bone, which has been
extensively studied for its biocompatible and osteo-regenerative properties, serving a
scaffold for modern bone graft substitutes.[152–154] As such, HA is widely used for
coating orthopedic implants where a strong interface with bone is required and as a
bone cement for craniofacial repair.[155, 156] However, HA is brittle in nature and has
a slow in vivo degradation rate which limits its applications to coatings for orthopedic
implants.[153, 157–159] To overcome these issues, HA may be densified through sintering
to improve mechanical strength and or through ionic substitutions to enhance bioactivity
and mechanical strength.[57–59, 158–163]
The pressing and sintering of HA have been known to improve its ultimate compressive
strength and toughness.[57–59, 158–163] Sintering can occur as low as 800 °C with the
final sintered density serving as a function of the particle size distribution and agglomeration
characteristics of the starting HA powder.[160, 161] For temperatures greater than 700 °C,
HA begins to decompose into different phases such as tricalcium phosphate (TCP), calcium
oxide (CaO) and water (H2O).[164] Overall, the presence of TCP in HA scaffolds affects the
strength, density, pore size, and degradation rate of HA.[163, 165] TCP degrades faster than
HA in vivo. Stoichiometric HA has been generally accepted as having a hexagonal P63/m
structure with chemical formula Ca10(PO4)6(OH)2 to denote the chemical composition
and symmetry composing the crystal unit cell.[164, 166] This apatite structure is flexible,
which can be substituted by various elements, such as Na, Mg, K, Sr, Zn, Ba, Cu, Al, Fe,
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F, Cl, and carbonate ions.[57, 58, 163] Alteration of the chemical formula of HA through
substitutions can alter its bioactivity, which is a similar approach to modify the bioactivity
of bioglasses.[159]
In improving the bioactivity of a material it is critical for the material to support
cell attachment and the extracellular matrix which contains bioactive factors to induce
regeneration.[167] When manganese is substituted into the HA lattice (MnHA) the MnHA
has the attractive feature of improving cellular adhesion.[168–172] Manganese (Mn) is
an essential trace metal found in all tissues and is required for normal amino acid, lipid,
protein, and carbohydrate metabolism.[173, 174] Mn plays a crucial role in cellular sig-
naling, especially in the activation of integrins; receptors that mediate cellular interactions
between the extracellular matrix and ligands on cell surfaces.[162, 175] The ligand affinity
increases for integrins in the presence of Mn ions, promoting cellular adhesion and possibly
having the ability to enhance osteogenesis.[175, 176] The development of new tissue
engineered scaffolds that provide mechanical support as well as repair and regeneration of
damaged or diseased bone may readily benefit from the introduction of Mn into current HA
scaffolds.[153]
MnHA has been previously synthesized through various wet synthesis techniques.[162,
177–186] Many of these studies examine the stability of MnHA through varying the wt%
of manganese or the calcination temperature. Mayer et al. attempted to incorporate
manganese up to 6 wt % via wet synthesis which decomposed at 600 °C into β-TCP.[162,
182, 187] Other attempts to incorporate up to 5 wt % manganese followed by calcination
at 800 °C, by Paluszkiewicz et al., resulted in phase purity up to 1 wt % manganese.[183]
The phase stability of MnHA at varying manganese wt % is well understood but there are
few studies on the effect of manganese substitution and mechanical properties. Ramesh
et al. produced MnHA through a wet milling technique and observed a decrease in the
Vickers hardness of sintered MnHA up to 1 wt % related to density.[188] Herein we report
a facile one-step room temperature ion exchange method to synthesize MnHA, as well
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as a systematic study of the sintering behavior, microstructural evolution and flexural
strength over a series of temperatures to determine the suitability of MnHA for biomedical
applications. The relationship between mechanical properties, microstructure and phases
helps identify suitable biomedical applications for pure MnHA and its decomposition
products.
4.2 Materials and Methods
4.2.1 Materials
The following materials were purchased from Acros Organics: Ammonium phosphate
dibasic (99+%), sulfuric acid (95-98%), stearic acid (97%), and potassium bromide
(IR grade). Calcium nitrate (99+%), manganese chloride tetrahydrate (99+%), and
ammonium hydroxide (29.45%) were purchased from Fisher Scientific.
4.2.2 HA and MnHA synthesis
HA was synthesized via a wet chemical method. An aqueous solution of ammonium
phosphate dibasic (80 mM) was added drop-wise to an aqueous calcium nitrate solution
(225 mM) at room temperature with the calcium to phosphate ratio maintained at 1.667.
Ammonium hydroxide was used to raise the pH of both solutions above 11 prior to mixing
the two solutions. Once the two solutions were completely mixed, the temperature of the
solution was raised to 95 °C for five hours, and then it was cooled to room temperature and
aged for two days under constant stirring. The precipitates were collected via centrifugation
and washed 3 times with de-ionized, 2 times with ethanol and vacuumed dried.
MnHA was synthesized through an ion-exchange procedure. A salt solution of MnCl2
was prepared at a concentration of 0.02 M and the pH was adjusted to 2.7 with dilute
sulfuric acid. Previously synthesized HA was immersed in the ion-exchange solution at
0.5 g/dL and sonicated for one hour at room temperature with intermittent stirring. The
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ion-exchanged HA was collected by centrifugation, washed 3 times with DIW and then
vacuumed dried.
The collected precipitates were ground with a mortar and pestle for 30 minutes into
a fine powder. The resulting powders were then milled (SPEX 8000 Mixer/Mill) for 10
minutes in a steel canister with alumina mixing balls.
4.2.3 Pellet preparation and sintering
SPEX milled HA and MnHA powders were uniaxially pressed into pellets using a bench
top Carver press (Carver Model C). Green bodies were prepared by pressing 0.3 g of milled
powder in a 13 mm steel die well lubricated with stearic acid and acetone at a pressure
of 150 MPa for 10 s. To improve the final green densities of the green bodies, uniaxially
pressed pellets were further compacted through cold isostatic pressing. Uniaxially pressed
pellets were vacuumed sealed in latex bags and then cold isostatic pressed at 210 MPa for
30 s.
Pellets were sintered at various temperatures (900 to 1300 °C for HA specimens and
700-1300 °C for MnHA specimens at 100 °C intervals) in air with a soaking time of one
hour in a chamber furnace (CM, 1610FL). Specimens were heated at a ramp rate of 15
°C/min to the soaking temperature and then cooled to room temperature at a rate of 15
°C/min. A total of 10 pellets of HA or MnHA were sintered for each temperature point.
4.2.4 Characterization
The milled as-synthesized HA and MnHA powders were examined with a FEI Tecnai
T12 S/TEM transmission electron microscope (TEM). Powders were dispersed in ethanol
via sonication and deposited onto a copper TEM grid with a carbon film. As-synthesized
HA and MnHA, along with sintered HA and MnHA specimens were assessed for phase
purity using a Bruker D2 Phaser X-ray diffractometer (XRD) with a copper target. Powder
diffraction patterns were acquired over 2-θ ranging from 10-90° with a step size of 0.02°
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and a scan rate of 1.25 seconds per step.
Density measurements were performed on the final green bodies and sintered pellets
using Ohaus digital balance with an accuracy of 1 mg and a caliper (Mitutoyo) with an
accuracy of 0.01 mm. Pellet height and diameter were measured in triplicates for each
pellet and the average diameter and height were used to calculate the pellet density.
A Tinius Olsen (150KS model) was used to determine the biaxial flexural strength on
sintered 13 mm pellets using a 1000 N load cell at a crosshead speed of 0.01 mm/minute. A
pin-on-disc fixture set up was used according to ASTM F 394.[189] The modulus of rupture
was calculated by the following equations:
S = 0.2387P
X − Y
d2
(1)
where S is the maximum center tensile stress (MPa) and P is the total load (N) causing
fracture,
X = (1 + ν) ln((
B
C
)2) + (
1− ν
2
)(
B
C
)2 (2)
Y = (1 + ν)[1 + ln[(
A
C
)2]] + (1− ν)(A
C
)2 (3)
where ν is Poisson’s ration, 0.27, A is the radius of the support circle (mm), B is the radius
of the loaded area or pin tip (mm), C is the radius of the specimen and d is the specimen
thickness at the point of fracture.
The microstructure of sintered HA and MnHA pellets was examined using a JEOL 6330F
field emission scanning electron microscope (FESEM) operating at 5 kV. The fracture surface
of sintered HA and MnHA pellets were sputter coated with gold palladium (SEM coating
unit E5100, Polaron Instruments Inc.) and used for microstructure analysis.
FESEM was also used to determine the grain size of HA pellets sintered over the
temperature range of 1000 to 1300 °C. FESEM was used since the average grain size of
certain specimens were less than the resolution limit of optical microscopy. Sintered pellets
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were polished to a 1 µm finish and then thermally etched for 30 minutes at 100 °C below
the sintering temperature. The average grain size was determined from FESEM images
using the line intercept method.
4.3 Results and Discussion
4.3.1 Results
4.3.1.1 Powder Characterization
SPEX milled as-synthesized HA and MnHA powders were characterized with TEM for
particle size analysis. Micrographs of HA and MnHA powders are depicted in Figure 4.1.
Both powders have morphologies of small rods with an average aspect ratio of 2.6 ± 0.8
for HA and 2.4 ± 0.7 for MnHA particles. HA particles (n = 151) have an average length of
35 ± 11 nm and an average width of 14 ± 3 nm. Similar to HA, MnHA particles (n = 155)
have an average length of 36 ± 11 nm and a width of 16 ± 4 nm.
Figure 4.1: TEM micrographs of SPEX milled HA (a) and MnHA powders (b).
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4.3.1.2 XRD Characterization
Powder diffraction patterns of the as-synthesized and heat-treated HA are depicted in
Figure 4.2. The as-synthesized material displays broad peaks and is identified as HA based
on JCPDF 9-432. At 800 °C, the observed peaks become more intense with no extraneous
peaks. The indexed peaks for HA continue to increase in intensity up to 1200 °C and
decrease at 1300 °C. Decomposition of HA is observed around 900 °C with the emergence
of calcium oxide (CaO) and β-tricalcium phosphate (β-TCP) peaks indexed at 27.8° and
29.68° 2θ for β-TCP and 37.4° for CaO. At 1300 °C, HA decomposes further and α-TCP peaks
started to emerge.
In comparison to the as-synthesized HA, the as-synthesized MnHA exhibits the same
powder diffraction pattern indicative of a pure Mn substituted HA, as shown in Figure
4.3. Unlike HA, MnHA start to decompose to β-TCP and manganese oxide (Mn3O4) at
a temperature as low as 800 °C, Figure 4.3, with continuous decomposition at higher
temperatures. At 1200 °C further decomposition into α-TCP is observed producing a mixture
of α-TCP, β-TCP, and Mn3O4.
4.3.1.3 Density and Biaxial Flexural Strength
After sintering but prior to density measurements and mechanical testing the physical
appearance of the sintered pellets was observed. Sintered HA pellets underwent shrinkage
at all temperatures but maintained their white appearance. In contrast, the MnHA pellets
not only underwent shrinkage but also resulted in a change in physical appearance which
is depicted in Figure 4.4. The initial green pellet is light pink but after sintering at 700 °C
turns dark blue. Subsequent sintering temperatures resulted in further color transitions
with gray pellets observed at 800 °C, yellow from 900 to 1000 °C, reddish brown at 1100
°C, and black from 1200 to 1300 °C.
The initial green densities, after cold isostatic pressing, and final sintered densities are
summarized in Table 1 along with the percent densified. Green bodies of HA have an
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Figure 4.2: Powder XRD pattern of as-synthesized HA (a) and HA heat treated at: 800
°C (b), 900 °C (c), 1000 °C (d), 1100 °C (e), 1200 °C (f), and 1300 °C (g). Non labeled
peaks correspond to observed reflections from pure HA.
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Figure 4.3: Powder XRD pattern of as-synthesized MnHA (a) and MnHA heat-treated
at: 400 °C (b), 500 °C (c), 600 °C (d), 700 °C (e), 800 °C (f), 900 °C (g), 1000 °C (h),
1100 °C (i), 1200 °C (j), and 1300 °C (k). Non labeled peaks correspond to observed
reflections from pure HA.
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Figure 4.4: Photograph of green and sintered MnHA pellets. From left to right: green
MnHA followed by MnHA heat-treated at 700-1300 °C at 100 °C increments. The pellet
size also decreases from left to right.
average density around 1.8 g/cm3, while MnHA have a density around 1.65 g/cm3. The
final densities of HA and MnHA pellets at various soaking temperatures are depicted in
Figure 4.5. A one way ANOVA analysis was performed to determine statistically significant
differences. There was a statistically significant difference (p < 0.05) in HA densities (p
= 5.93e-16) and MnHA densities (p = 5.38e-35) over the studied temperature ranges.
After sintering at 900°C the HA pellets start to densify followed by increased densification
upon sintering at 1000 °C. Within the temperature range of 1000 to 1300 °C, HA pellets
continue to densify with increasing temperature until 1300 °C, where a maximum density
of 2.99 g/cm3 is achieved. For MnHA specimens the sintered density continuously increases
over the studied temperature range which is reflected in the percent densified. An abrupt
increase in density is observed from 900 °C to 1000 °C corresponding to a density of 2.02
and 2.53 g/cm3, respectively. From 1000 to 1300 °C the density continues to increases and
reaches a maximum density of 2.68 g/cm3 at 1300 °C.
Due to the compressive and bending forces typically exerted on bones, the flexural
strength of the sintered pellets were evaluated by a modulus of rupture (M.O.R) test, and
the mechanical properties are depicted in Figure 4.6. A one way ANOVA was performed to
determine statistically significant differences. There was a statistically significant difference
(p < 0.05) in M.O.R between HA (p = 1.33e-7) and MnHA (p = 4.4e-13) over the studied
temperature ranges. The M.O.R of sintered HA pellets ranges from 23 MPa at 1300 °C to 78
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Figure 4.5: Densities of sintered HA and MnHA pellets as a function of temperature.
Average densities are plotted ± standard deviation (n ≥ 4).
MPa at 1000 °C. Initially the M.O.R increases from 900 to 1000 °C and then continuously
decreases from 1000 to 1300 °C. Unlike HA, the M.O.R. values of the sintered MnHA
continuously increase over the temperature range of 800 to 1300 °C ranging from 18 MPa
at 800 °C to 64 MPa at 1300 °C. From 800 to 1000 °C there is a small gradual increase in
the M.O.R values followed by a rapid increase over the range of 1000 to 1200 °C with a
small increase from 1200 to 1300 °C.
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Figure 4.6: Mechanical properties of sintered HA and MnHA pellets as a function of
temperature. Average M.O.R values are plotted ± standard error (n ≥ 4).
4.3.1.4 FESEM Characterization
The sintering behavior of heat-treated HA and MnHA specimens was further investi-
gated using FESEM. Fractured surfaces of sintered HA pellets are depicted in Figure 4.7.
Specimens heat treated at 900 °C exhibit signs of sintering where the HA particles have
fused together and the pores between particles have started to round, but there are still a
large number of pores present in specimens. At 1000 °C, the HA specimens have sintered
completely with few rounded pores present. At temperatures greater than 1000 °C, grain
growth is observed with increasing temperature. Pores remain over the range of 1000 to
1300 °C with a rounded morphology and grow in size with increasing temperature.
Fracture surfaces of heat-treated MnHA pellets are depicted in Figure 4.8. At 700 °C
the particles of the green body are identifiable and there is no indication of particles fusing
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at this temperature. Unlike HA, MnHA starts to sinter at a temperature as low as 800
°C, where individual particles have started to fuse together, but the overall structure still
demonstrates a porous network. The onset of decomposition of MnHA also occurred at
800 °C. The pellets continue to sinter with increasing temperature and the porosity of the
sintered body slowly decreases. Significant porosity increase is present at 1200 °C, which is
100 °C lower than that observed in HA sintering.
Since the sintering of HA specimens was complete at 1000 °C, FESEM was used to for
grain size analysis over the temperature range from 1000 to 1300 °C. Figure 4.9 shows
polished and etched surfaces of HA sintered bodies. The measured grain size was 110 nm,
305 nm, 765 nm, and 1.8 µm from 1000 to 1300 °C. A relationship between the M.O.R and
the inverse square root of grain size of sintered HA bodies is depicted in Figure 4.10. The
M.O.R increases with decreasing grain size following a linear relationship from 1000 to
1200 °C, which follows the classical Hall-Petch relationship with the following relation
M.O.R. = τo + kd
−1/2 (4)
where τo and k are material constants and d is the average grain size.
4.3.2 Discussion
The ceramic phase of bone is a poorly crystalline phase of HA with numerous impurities
which influence HA’s thermal stability, and mechanical and bioactive properties. Pure HA is
normally stable until 1350 °C before decomposing into calcium oxide (CaO) and tricalcium
phosphate (TCP).[176] In the current study, the decomposition of the as-synthesized HA
into CaO and β-TCP started at 900 °C. HA with chemical impurities, such as carbonate, have
been shown to degrade at temperatures as low as 800 °C.[190] The synthesis method used
in this study was exposed to an ambient atmosphere which resulted in partial carbonation of
the precipitated HA, as previously reported.[65] As the temperature increases from 900 to
1200 °C, the HA phase increases in crystallinity with temperature. A transition is observed
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Figure 4.7: Cross sections of sintered HA pellets at 900 °C (a), 1000 °C (b), 1100 °C (c),
1200 °C (d), and 1300 °C (e). Micrographs (a-e) were taken at 10,000X magnification.
at 1300 °C, where the peak intensity of the HA phase decreases in intensity compared to
1200 °C. The relative intensity between the decomposed phases β-TCP and CaO to HA is
greater at 1300 °C compared to 1200 °C indicating that the decomposition of the HA phase
increases with the sintering temperature.
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Figure 4.8: Cross sections of sintered MnHA pellets at 700 °C (a), 800 °C (b), 900 °C (c),
1000 °C (d), 1100 °C (e), 1200 °C (f), and 1300 °C (g). Micrographs (a-g) were taken at
10,000X magnification.
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Figure 4.9: FESEM images of the etched surface of HA pellets sintered at 1000 °C
(a), 1100 °C (b), 1200 °C (c), and 1300 °C (d). Note the differences in magnification.
Micrographs (a) and (b) were taken at 25,000X. Micrographs c and d were taken at
5,000X.
The thermal stability of MnHA was investigated over the range of 400 to 1300 °C. A
larger temperature range than HA was selected since manganese oxides have been shown
to undergo phase transitions as low as 400 °C.[191] The as-synthesized MnHA powder
diffraction pattern matches the observed pattern for the as-synthesized HA indicating
successful substitution of Mn into the HA lattice. The phase purity of MnHA is maintained
up to 800 °C where significant decomposition into β-TCP and Mn3O4 has occurred. Upon
further heating, MnHA decomposes into α-TCP, β-TCP, and Mn3O4 at 1200 °C; these phases
remain present at 1300 °C. The transformation of β-TCP to α-TCP is typically observed
around 1125 °C.[192]
The microstructure of HA and MnHA were investigated with FESEM over the tempera-
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Figure 4.10: Modulus of rupture of HA as a function of the inverse square root of the
grain size over the temperature range from 1000 °C to 1300 °C.
ture range studied for mechanical testing. Pure HA normally starts to sinter around 1000
°C [176], but in this study HA was observed to sinter at 900 °C. HA nanorods with similar
reported aspect ratios around 2.4 and an average length around 55 nm have been shown to
start to sinter as low as 850 °C.[193] The sintering behavior at low temperatures resulted
from surface defects such as OH- vacancies and vacancies created from the release of
carbonate groups which lowers the activation energy for surface diffusion.[193] Proceeding
from 900 to 1000 °C sintering has completed which is observed in the closure of the pores
between particles and an increase in the sintered density which plateaus around 95 % of
the theoretical density (3.156 g/cm3) over the rest of the studied temperature range. The
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grain size and pore size increase with the sintering temperature. The grains grow as part of
the recrystallization and growth process, while the increase in pore size is a result of the
dehydroxylation process of HA. At temperatures exceeding 800 °C HA starts to lose water;
during this process pressure builds from water vapor and results in blowhole formation
with larger blowholes at higher temperatures.
In the case of MnHA sintering occurred around 800 °C, which coincided with the onset
of decomposition. The decomposition of MnHA over the temperature range of 800 to 1000
°C results in a highly porous and interconnected structure which may be attributed to the
counteracting processes of both sintering and dehyrdoxylation of HA. The overall porosity
slowly decreases over this temperature range. The porosity significantly decreases at 1100
°C, which is reflected in the increase in densification. The pores have become isolated and
are lager in size. A similar microstructure was observed at 1200 and 1300 °C, but with less
porosity and larger pores. The porosity over the range of 1100 to 1300 °C is related to the
decomposition products of HA.
Interestingly over this temperature range the sintered densities increased slowly as seen
in the percent densification, and the higher sintered density at 900 °C compared to 1000 °C
is attributed to the greater initial green density of 900 °C specimens compared to 1000 °C.
The differences between these green densities were a result of variation in batch to batch
processing of MnHA where the degree of agglomeration influences the final green density
after pressing.
HA and MnHA display different densification and mechanical behavior as a function
of temperature. The difference in densification behavior is a result of their discrepancy in
thermal stability which influences the microstructure as discussed above. Meanwhile, the
mechanical behavior is closely related to the microstructure of the material. HA pellets
achieved a maximum M.O.R around 78 MPa, which compares favorably with the values
reported in literature of bulk HA which range from 45 to 150 MPa.[158, 194–201] The
wide range of reported values results from differences in processing and impurities. Hot
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isostatic pressing which results in a more homogenous microstructure and fewer defects
was used by Boilet et al. and Raynaud et al. to achieve flexural strengths in excess of 100
MPa.[200, 201] Kana et al. observed that carbonated HA has a lower flexural strength, 45
MPa, when compared to pure HA, 75 MPa.[198] The literature values of flexural strength
and the observed maximum M.O.R are also within the range of reported flexural moduli of
natural bone which ranges from 35 to 283 MPa.[202]
The M.O.R shown in Figure 4.6 depicts that the M.O.R initially increases for HA peaking
at 1000 °C and then decreases over the rest of the temperature range. The initial increase
is a result of fewer pores from improved densification from 900 to 1000 °C. After 1000 °C
the M.O.R continuously decreases with increasing temperature. Three mechanisms may
be attributed to the decreased M.O.R: (1) larger grains, (2) higher porosity, and (3) more
decomposition. Improved strength and hardness are observed in ceramics with smaller
grains which provide more barriers to crack propagation compared to larger grains. Pores
are sites of concentrated stress which reduces the stress need for crack initiation and
propagation leading to premature failure. The decomposition process of HA results in pore
formation and inhomogeneous microstructure which also reduce the overall strength. The
main mechanism resulting in a decrease in the M.O.R is an increase in grain size from 1000
to 1200 °C which follows the classical Hall-Petch relation. A similar Hall-Petch relation was
observed in the hardness of nanocrystalline HA sintered over the temperature range of 850
to 1200 °C with grain sizes ranging from 65 to 730 nm by Wang et al.[203] At 1300 °C the
M.O.R deviates from the Hall-Petch relation as a result of HA decomposition to TCP. The
reduction in M.O.R is a result of increased grain size, porosity and pore size.
The increase in the M.O.R as a function of temperature for MnHA is attributed to the
sintering behavior of the material, as MnHA densifies the degree of porosity decreases.
At sintering temperatures lower than 1100 °C, a highly porous and interconnected mi-
crostructure is observed. The large degree of porosity and the interconnectivity of the pores
result in a fragile structure. The formation of a denser microstructure with isolated pores
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observed from 1100 to 1300 °C results in an increase in the M.O.R attributed to a reduction
in porosity. The maximum M.O.R observed for MnHA is around 64 MPa at 1300 °C which is
lower than the maximum M.O.R observed for pure HA. Sintering at 1200 °C, the HA phase
has almost completely decomposed with α-TCP, β-TCP, and Mn3O4 being the dominate
phases. The flexural strength of β-TCP is weaker than natural bone and is often detrimental
to the mechanical properties of HA when presents as an impurity.[197, 204] The maximum
observed M.O.R of MnHA of 64 MPa compares favorably with literature values. Studies on
the mechanical properties of metal substituted β-TCP and sintered laminate β-TCP have
shown flexural strengths ranging from 20 to 160 MPa.[205, 206] Despite the decomposition
of MnHA to TCP, the fast degradation rate of TCP sometimes is a desirable property in
many biomedical applications. TCP has been mixed with HA to produce tissue engineering
scaffolds with accelerated degradation rate compared to pure HA scaffolds.[207]
4.4 Conclusion
The sintering behavior of pure HA and MnHA was studied for the suitability of MnHA
in load bearing applications. The maximum sintered density achieved for was 2.99 and
2.69 g/cm3 for HA and MnHA, respectively. Decomposition of MnHA into TCP and Mn3O4
occurred at 800 °C, while HA pellets started to sinter at 900 °C with partial decomposition
to β-TCP and CaO. The maximum M.O.R achieved for HA and MnHA were 78 and 64 MPa,
respectively. The low thermal stability of MnHA suggests that a faster dissolution rate in
vivo than pure HA is expected.
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CHAPTER FIVE
In Vitro Evaluation of MnHA, FeHA, and CoHA
5.1 Introduction
Many transition metals are required in trace amounts for normal biological function.
Manganese, iron, and cobalt are essential elements but normal dietary intake is generally
less than 100 mg/day.[208] When the elemental concentration exceed what is necessary
for biological function these elements can be toxic. At high concentrations, toxic effects can
arise due to the redox ability which promotes the formation of damaging free radicals such
as reactive oxygen species.[208–210] As such, the substitutions of manganese, iron, and
cobalt into the HA lattice may alter the biocompatibility.
HA is well-known for its biocompatibility, biodegradation, and ability to accommodate a
wide range of substituents. In natural bone a wide range of trace elements are found such as
Na, Mg, K, Zn, Ba, Cu, Fe, Mn, F, and carbonate ions.[57, 58, 163] Many substitutions have
been shown to alter the biocompatibility and bioactivity of pure HA such as are Mg2+, Sr2+,
CO32-, and SiO44- rendering the substituted HA more biocompatible.[159] When substituted
into the HA lattice manganese and iron have both been shown to have a positive influence
on osteoblast behavior.[60, 168–172]
In vitro assays are powerful tools that aid in the assessment of a materials toxicity. Even
though HA is a well know biocompatible and bioactive biomaterial, changes to its chemical
formula may result in a change in biocompatibility. Using commonly used in vitro assays
the biocompatibility of FeHA, CoHA, and MnHA are assessed and compared to pure HA in
this chapter for the assessment of the use of transition metal substituted HA in vivo.
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5.2 Materials and Methods
5.2.1 Cell Culture
Mouse calvaria 3T3-E1 (MC3T3-E1) cells were used to assess the biocompatibility of
MnHA, FeHA, and CoHA powders compared to pure HA. Cells were grown in alpha modified
eagles medium (MEM) supplemented with 10 % fetal bovine serum and 1 % penicillin-
streptomycin at 37 °C under an atmosphere of 5 % CO2 with the medium being changed
every other day until 90 % confluence.
5.2.2 Cellular proliferation
Cellular proliferation was assessed using either an alamarBlue or 3-(4,5-dimethylthiazol-
2-yl)-2,5-diphenyltetrazolium (MTT) assay. In principle, both assays assess the metabolic
activity of living cells through the reduction of a dye. Cellular proliferation in the presence
of FeHA compared to pure HA was assessed with alamarBlue, and as a cost saving measure
cellular proliferation in the presence of MnHA and CoHA were assessed with the MTT assay.
5.2.2.1 Cellular proliferation in the presence of FeHA
Cellular proliferation was assessed at 1, 3 and 7 days via alamarBlue assay. Cells were
seeded at a density of 20,000 cells per well in a 24-well plate (n ≥ 3). Cells were allowed
to adhere for four hours, after which the medium was changed to a medium containing
FeHA or HA particles dispersed at concentrations of 20 µg/mL or 50 µg/mL. Powders
were sterilized by immersion in 70 % ethanol for 30 minutes while under sonication. The
powders were collected by centrifugation, rinsed with sterile filtered DIW three times, and
re-dispersed in supplemented α-MEM. The medium was changed every other day. At the
specified time points, cells were rinsed with a phosphate buffer saline solution and the
medium was refreshed with 1 mL of ‘powder-free’ medium. AlamarBlue was added at
1/10th the medium volume and incubated at 37 °C for 4 hours. Aliquots, 200 µL, were
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taken from each specimen in triplicate and the absorbance was measured using a plate
reader (µquant from Biotek) at 570 and 600 nm. The percent reduction in alamarBlue was
calculated by:
PercentReduced = (A570 −RoA600)100 (1)
where Ro is a correction factor, A570 and A600 are the absorbance values at 570 and 600
nm, respectively. Data was represented as the mean ± the standard deviation. Statistical
significance was tested with a student t-test with two tails, and differences were considered
significant if p < 0.05.
5.2.2.2 Cellular proliferation in the presence of MnHA or CoHA
Cellular proliferation was assessed at 1, 3 and 7 days via MTT assay. Cells were seeded
at a density of 20,000 cells per well in a 24-well plate (n ≥ 3). Cells were allowed to adhere
for four hours, after which the medium was changed to a medium containing either MnHA,
CoHA, or HA particles dispersed at concentrations of 20 µg/mL or 50 µg/mL. Powders
were sterilized the same as FeHA powder was in the previous section. At the specified time
points, cells were rinsed with a phosphate buffer saline solution, and the medium was
replaced the medium was refreshed with 1 mL of ‘powder-free’ medium. A 5 mg/mL MTT
working solution was added equal to 1/10th the medium volume. The treated cells were
incubated for 4 hours at 37 °C. The medium was then removed and a solution of 0.04 N HCl
in isopropanol was added to dissolve the formed crystals. Aliquots of 200 µL were measured
using a plate reader (µquant from Biotek) at 560 nm and the background absorbance
was measured at 680 nm. Data was represented as the mean the ± standard deviation.
Statistical significance was tested with a student t-test with two tails, and differences were
considered significant if p < 0.05.
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5.2.3 Cytotoxicity of MnHA, FeHA, and CoHA powders
Lactate dehydrogenase (LDH) is an enzyme bound to the cell membrane and can be
used to assess the integrity of the cell membrane. The activity of released LDH was used to
quantify the cytotoxicity of MnHA, FeHA, and CoHA powders. LDH activity was evaluated
with a LDH assay kit from Thermo Scientific. In brief, cells were seeded at 10,000 cells per
well in a 96 well plate (n ≥ 3) and allotted four hours for attachment. The medium was then
removed and replaced with medium containing HA, MnHA, FeHA, or CoHA nanoparticles
at 20, 50 or 100 µg/mL. Control cells were treated with 10 µL sterile DIW, which was used
to determine the spontaneous LDH release, and 10 µL lysis solution, which was used to
determine the maximum LDH release. After 24 hours of incubation, the release of LDH into
the medium was determined by adding 50 µL working solution and incubated in the dark
at room temperature for 30 min. Then the absorbance of the supernatant was measured at
480 nm, and a background measurement was performed at 680 nm. Data was represented
as the mean ± the standard deviation. Statistical significance was tested with a student
t-test with two tails, and differences were considered significant if p < 0.05.
5.3 Results and Discussion
5.3.1 Results
5.3.1.1 FeHA
Biological evaluations were performed on Fe2+3+HA since it displayed superparamag-
netism and had a higher magnetization compared to Fe2+HA. FeHA and HA specimens did
not demonstrate any significant difference in supporting cell proliferation at particluate
concentrations of 20 and 50 µg/mL, see Figure 5.1 (a). However, cellular proliferation
was affected in a dose dependant manner. At a dose of 50 µg/mL, cell proliferation for HA
and FeHA particles was significantly less compared to a dose of 20 µg/mL, from day 1 to
day 3, respectively. However, this initial effect on proliferation was ameloriated by day 7.
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Compared to 20 µg/mL, a 50 µg/mL FeHA dose resulted in a lower degree of proliferation
at day 7 than a 50 µg/mL dose HA, but the increase in proliferation from day 3 to day 7 is
signigicant. The dose depedenant response was also observed in LDH activity as shown in
Figure 5.1 (b). Higher powder concentrations resulted in higher LDH activity, but FeHA was
observed to be less toxic compared to HA at the same dose. Cells treated with sterile DIW
and a lysis solution were used as controls for LDH activity. The minimum release (min)
corresponds to the spontaneous release of LDH from untreated cells, and the maximum
release (max) corresponds to the LDH activity where untreated cells were lysed resulting in
complete cell death.
Figure 5.1: Proliferation of MC3T3-E1 cells in the presence of FeHA and pure HA (a).
LDH activity from MC3T3-E1 cells treated with FeHA or pure HA compared to the
spontaneous (min) and maximum (max) LDH released from untreated MC3T3-E1 cells
(b). *p < 0.05
5.3.1.2 CoHA
The effect of CoHA on cellular proliferation was inhibitive, while HA supported cell
proliferation, as seen in Figure 5.2 (a). The HA treated cells proliferated at the same rate
78
over the course of one week. In contrast the CoHA treated cells did not proliferate from day
1 to 3 with the optical density (O.D.) remaining the same while the cell number decreased
from day 3 to 7 with a decrease in O.D..
The LDH assay results are presented in Figure 5.2 (b). There is no statistical difference
(as determined by a 2-tailed t-test) between the spontaneous release of LDH in cells treated
with medium alone and those treated with HA or CoHA.
Figure 5.2: Proliferation of MC3T3-E1 cells in the presence of CoHA and pure HA (a).
LDH activity from MC3T3-E1 cells treated with CoHA or pure HA compared to the
spontaneous (min) and maximum (max) LDH released from untreated MC3T3-E1 cells
(b).
5.3.1.3 MnHA
Both HA and MnHA supported cell proliferation as seen in Figure 5.3 (a) and there
were no statistically significant differences between HA and MnHA treated cells of equal
concentrations. Proliferation was affected in a dose dependent manner. The 50 µg/mL
dose of HA and MnHA resulted in a statistically significant difference at day 3 compared to
cells treated with 20 µg/mL HA. At day 7 where there is a statistically significant difference
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between cells treated with 20 µg/mL and 50 µg/mL HA or MnHA. Overall, no statistically
significant differences were observed when cells were treated with the same dose of HA or
MnHA.
The LDH assay results are presented in Figure 5.3 (b). There is no statistically significant
difference between the spontaneous release of LDH in cells treated in medium alone and
those treated with HA particles or MnHA at 20 µg/mL. Interestingly a dose of 50 and
100 µg/mL MnHA resulted in a decrease in LDH activity that was a statistically significant
difference compared to the spontaneous LDH release control.
Figure 5.3: Proliferation of MC3T3-E1 cells in the presence of MnHA and pure HA (a).
LDH activity from MC3T3-E1 cells treated with MnHA or pure HA compared to the
spontaneous (min) and maximum (max) LDH released from untreated MC3T3-E1 cells
(b). *p < 0.05
5.3.2 Discussion
5.3.2.1 FeHA
Further testing of Fe2+3+HA was assessed in vitro due to the lucrative superparam-
agnetic property and larger magnetization than Fe2+HA. Proliferation was assessed with
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the alamarBlue assay. The active reagent in alamarBlue is reazurin, which is reduced
by metabolically active cells resulting in a change in color from blue to red. Increased
reduction in alamarBlue can be related to an increase in cell number. The proliferation of
MC3T3-E1 cells showed no cytotoxicity when Fe2+3+HA and HA were administered at the
same dosage (20 µg/mL). A higher administered dosage (50 µg/mL) of Fe2+3+HA showed
an initial inhibition of cellular proliferation at day 3 and negligible inhibition by day 7.
A cytotoxicity assay was also performed to assess the damage to the cell membrane. LDH
is a membrane bound protein that is released when the cell membrane is damaged. The
amount of LDH released is representative of the toxicity of a material. A dose dependent
response was observed similar to that in the proliferation assay. Still, FeHA was observed to
be less cytotoxic than HA at the same dose. The observed toxicity of HA is not atypical for
in vitro studies despite its in vivo compatibility. Many factors contribute to toxicity including
particle size and shape, surface charge and chemical composition.[211–213] The toxicity
of HA nanoparticles can be attributed to the release of Ca2+ disrupting the intracellular
Ca2+ homeostasis as observed by Motskin et al.[211] The use of in vitro characterization
is a valuable tool for screening the compatibility of biomaterials but the response is not
indicative of the in vivo performance. As the case for HA, it is a widely accepted biomaterial
with excellent in vivo performances, but its in vitro performances does not always reflect its
in vivo biocompatability.[214] This may be true with FeHA too, future studies to examine
the in vivo performance of FeHA will be conducted to confirm its biocompatibility as an
implantable material.
5.3.2.2 CoHA
Prior to utilization in biomedical applications, the biocompatibility of CoHA needs to
be evaluated. While the results from the proliferation experiment may initially suggest
that CoHA is not biocompatible, the findings from the LDH assay, Figure 5.2 (b), suggest
differently. The discrepancy between these results suggests that either a catalytic reaction
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occurs between CoHA and the cell culture medium or the release of cobalt ions inhibits
cell proliferation. The cell culture studies presented in this chapter are also limited in
that a single cell line was used. Various cell lines may react differently to differing culture
conditions. For example, Wu et al. established that low amounts of cobalt incorporation
into a scaffold resulted in no cytotoxicity in human bone marrow stromal cells (BMSCs).
Additionally, cobalt ion release from the scaffold induced VEGF protein secretion, HIF-1α
expression, and bone-related gene expression in BMSCs, indicating that while cobalt ions
result in a response that mimics hypoxic conditions, they did not induce toxicity or cell
death.[215] Additionally, in vitro cell culture conditions are simple and static, as compared
to in vivo conditions. In vivo response to cobalt release from CoHA may differ from that
seen in vitro. The cell culture results obtained in this chapter are not sufficient to draw
any strong conclusions, and the CoHA material needs to be further investigated for its
biocompatibility.
5.3.2.3 MnHA
Overall, the results from proliferation suggest that MnHA is biocompatible, while the
results from the LDH assay are inconclusive. The proliferation results suggest that MnHA
does not affect the metabolic behavior of the cells as observed in the inhibitive effect of
CoHA and is as biocompatible as pure HA. The increase in MnHA concentration resulted in
a decrease in LDH activity. This may result from an interaction between MnHA particles
and LDH or released manganese ions and LDH. Han et al. studied the effect of copper,
silver, and titanium dioxide nanoparticles on their potential to inactivate LDH and observed
copper nanoparticles interfered with LDH due to the interaction between LDH and copper
ions as a result of copper dissolution.[216] Titanium dioxide particles adsorbed LDH but
did not inactivate the enzyme.[216] In the case of titanium dioxide the LDH activity was
observed to increase with nanoparticle concentration up to a critical concentration after
which LDH activity decreased, which was attributed to adsorption of LDH to titanium
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dioxide nanoparticles.[216] Interaction between particles and commonly used viability
assays can make drawing strong conclusions on the toxicity of particles difficult even at low
particle concentrations.[217] Overall, results from the MTT assay suggest that MnHA does
not affect the metabolic activity of the cell and comparable to pure HA, while the results
from LDH assay are inconclusive. While in vitro assays are good indicators of a materials
biocompatibility it is not always indicative of in vivo performance. As with FeHA, future in
vivo studies should be performed to confirm its biocompatibility as an implantable material.
5.4 Conclusion
The biocompatibility of FeHA, CoHA, and MnHA were assessed and compared to pure HA
using a proliferation assay and cytotoxicity assay. The substitution of iron and manganese
did not significantly affect cellular proliferation, while the substitution of cobalt resulted in
inhibited cellular proliferation. Assessment of LDH activity indicate that FeHA and CoHA do
not damage the integrity of the cell membrane and the cytotoxicity is comparable to pure
HA, while results from MnHA are inconclusive due to interference between MnHA and LDH.
These effects are due to either the release of ions from the powders or particle interactions
with the cells. The inhibitive effects of CoHA on proliferation is most likely due to the
release of cobalt ions, which can create a hypoxic environment through the stabilization
of HIF-1α. This effect is not seen with iron or manganese ions. The release of ions
and/or particle interactions may inhibit LDH activity, which was observed in MnHA but not
FeHA or CoHA. Overall, iron- and manganese-substituted HA powders demonstrated good
biocompatibility, which makes these powders suitable for potential magnetic applications
and other biomaterial applications such as bone void filler. Cobalt-substituted HA is suitable
for potential magnetic applications where material can be removed rapidly from the body.
Further in vivo testing should be performed for all substituted HA powders.
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CHAPTER SIX
Mineralization of Type I Collagen with Iron Oxide for the Synthesis of
Magnetic Nanoworms
6.1 Introduction
In regards to tumor therapy applications, the particle properties, such as size and
shape, are important factors.[70–73] In both passive and targeted delivery applications,
the blood circulation time is an important factor in particle accumulation at the tumor
site. There is increasing evidence that non-spherical/anisotropic particles are less readily
taken up by macrophages, resulting in a slower clearance rate of the material, thereby
prolonging circulation.[72, 73] Non-spherical shapes also demonstrate improved targeting
efficiency, since the oblong shapes have more surface area compared to spherical particles
more binding events between the targeting ligand and target site can occur.[73] While in
circulation, non-spherical particles exhibit more lateral drift compared to spherical particles,
which follow streamlines, resulting in an increased likely hood of accumulating at the
tumor site.[73] Recently, the semi-flexible filomicelles as delivery vehicles have been shown
to have increased circulation time and accumulation in tumors compared to spherical
micelles.[76–78]
The rigid nature of the previously synthesized HA particles may result in short blood
circulation times. The main organic component of bone is type I collagen that is a long
and flexible filamentous protein. Biomimetic techniques have been successful at inducing
mineralization inside the gap zone of collagen fibers (namely, intrafibrillar mineralization)
with either calcium phosphate or silica.[218–220] The mineralization of a magnetic phase
within the gap zone of collagen may yield a semi-flexible and magnetic material suitable for
tumor therapy applications.
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Typical biomineralization approaches utilize macromolecules with charged functional
groups, such as carboxylates and amines.[218, 219] In the case of intrafibrillar mineral-
ization with calcium phosphate, a negatively charged macromolecule mimicking acidic
proteins is required to prevent premature precipitation of calcium phosphate while sup-
porting the deposition of calcium phosphate within the collagen fibers.[218] Intrafibrillar
mineralization with silica requires positively charged functional groups to attract negatively
charged silica.[219]
Iron oxides are another class of materials that are classified as a biomineral. Excess iron
ions within the body are stored as ferrihydrite within the globular protein ferritin.[221]
The accumulation and release of iron within ferritin is mediated through interactions with
the amino acids glutamate and aspartate. These amino acids have a carboxylate functional
group that interacts with iron ions through electrostatic interactions. The structure of
ferritin and its interactions with iron ions have been used to produce magnetic iron oxides
and manganese oxide nanoparticles under basic and reducing conditions.[222, 223]
Utilizing the principles of biomineralization, collagen fibers are templated with macro-
molecules with either carboxylate or amine functional groups and incubated in an iron
solution. Mineralization is induced by raising the pH of solution to induce precipitation of
iron oxide within collagen.
6.2 Materials and Methods
6.2.1 Materials
Type I collagen was extracted from rat tails, solubilized, and purified based on a protocol
reported by Rajan et al.[224] Poly-aspartic acid (Mw = 2000-11000 Da) and polyallylamine
hydrochloride (Mw = 15000 Da) were purchased from Sigma-Aldrich. A 2 % aqueous solu-
tion of osmium tetroxide solution was purchased from Electron Microscopy Sciences. The fol-
lowing chemicals were purchased from Acros Organics: iron chloride tetrahydrate (99+%),
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iron chloride hexahydrate (97+%), and 1-ethyl-3-(3-dimethylaminopropyl)carbodiimide
hydrochloride (98 +%). Ammonium hydroxide (29.45 %) was purchased from Fisher
Scientific.
6.2.2 Methods
6.2.2.1 Functionalization of collagen fibers
A two-step approach was employed to mineralize collagen fibers with iron oxide.
First, collagen fibers were formed by mixing acid solubilized type I collagen (3 mg/mL)
with a 0.2 M phosphate buffer (pH = 7.4) at a 1:1 (v:v) ratio for one hour. Colla-
gen fibers were collected via centrifugation and washed three times with de-ionized wa-
ter (DIW). Collagen fibers were incubated in a solution of 500 µg/mL polyallylamine
hydrochloride (PAH) or poly-aspartic acid (PASP) at 37 °C for one hour. 1-ethyl-3-(3-
dimethylaminopropyl)carbodiimide hydrochloride (EDC) was added at 0.02 g/mL to cross-
link PAH or PASP to the collagen fibers. The solution was incubated at 4 °C overnight to
allow for complete cross-linking. As a control, collagen fibers were cross-linked with EDC
in the absence of PAH or PASP prior to mineralization.
For transmission electron microscopy (TEM) characterization, collagen fibers were grown
on gold TEM grids by floating the TEM grid on top of the polymerizing collagen solution.
Functionalization with PASP or PAH was performed as described above by immersing the
TEM grid with collagen fibers in the respective solutions.
6.2.2.2 Mineralization of functionalizated collagen fibers
Functionalized collagen fibers (PAH or PASP templated) were immersed into a 40 mM
solution of iron chloride with FeCl2:FeCl3 ratio of 2:1 at 37 °C under the protection of a
nitrogen atmosphere. The fibers are incubated in the iron solution for one hour after which
the pH is rapidly adjusted with concentrated ammonium hydroxide to a pH > 10. The fibers
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are mineralized for one hour, collected, and rinsed through a combination of sonication
and magnetic decantation.
After observing that PASP functionalization promoted mineralization, the FeCl2:FeCl3
ratio was varied from 1:0, 1:2, 1:1, and 2:1 using a 4 mM iron solution. The fibers were
incubated in the iron solution at 37 °C with the protection of a nitrogen atmosphere for 1
hour. The pH was rapidly adjusted to a pH > 10, and the fibers were allowed to mineralize
overnight. Fibers were collected and rinsed as described above.
6.2.2.3 Characterization
Mineralized collagen fibers were observed using TEM (JEOL JEM-2010) at an accel-
erating voltage of 80 kV. For the ideal mineralized collagen fibers characterized using
attenuated total reflection-Fourier transform infrared spectroscopy (ATR-FTIR) and X-ray
diffraction. A Nicolet Magna 560 FT-IR spectrometer with an ATR setup was used to collect
infrared spectrum in the range of 4000-400 cm-1 at a 4 cm-1 resolution with 32 scans. A
Bruker D2 Phaser X-ray diffractometer (XRD) with a copper target was used to acquire
XRD patterns over 2-θ ranging from 10-70° with a step size of 0.02° and a scan rate of 1.25
seconds per step.
6.2.2.4 Synthesis of single collagen fibers
Single collagen fibers were synthesized by controlling the kinetics of collagen poly-
merization. Collagen polymerization was initiated by mixing a phosphate buffer (pH =
7.4) with acid soluble type I collagen at 1:1 (v:v) ratio on top of a TEM grid to induce
self-assembly of collagen fibers on the TEM grid. The polymerization process was simultane-
ously monitored by measuring the turbidity of the polymerizing collagen solution at 313 nm
using a microplate reader (µquant from Biotek). At selected time point, the polymerizing
collagen solution was rinsed away with DIW. Collagen fibers were stained with osmium
tetroxide for 30 minutes prior to TEM characterization.
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6.3 Results and Discussion
6.3.1 Results
Initially collagen fibers templated with PASP, PAH, or cross-linked fibers were mineralized
with a 40 mM iron chloride solution. After mineralization, the resultant fibers were black in
appearance and were attracted to a permanent magnet. Figure 6.1 depicts the mineralized
fibers for each of the aforementioned conditions. When the collagen fibers are templated
with PASP, Figure 6.1 (a), the characteristic d-banding pattern of collagen is observed
indicating successful mineralization within the gap zone. In contrast, the cross-linked
collagen fibers, Figure 6.1 (b) display minor d-banding with minerals on the surface, while
the PAH templated collagen fibers did not display any visible signs of d-banding only
minerals deposited on the surface.
Figure 6.1: Iron oxide mineralization of collagen fibers. Fibers templated with PASP (a),
control fibers cross-linked with EDC (b), and fibers templated with PAH (c).
The most prominent d-banding was observed in collagen fibers templated with PASP, so
further investigation was conducted on the effect of the Fe2+:Fe3+ ratio, which influences
the pathway of iron oxide formation, on PASP-templated collagen fibers (Figure 6.2). Iron
oxide particles were formed on the surface and within the gap zone of collagen fibers.
The observed d-banding pattern in the collagen fibers is the most pronounced when the
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Fe2+:Fe3+ ratio was 2:1 or 1:1, suggesting the formation of iron oxide inside the gap zone
of collagen fibers. When Fe2+:Fe3+ ratio is 1:0, light d-banding is observed but large
crystals are present on the surface of the fibers. For the case where Fe3+ is present and
the concentration of Fe3+ is less than that of Fe2+, the characteristic d-banding pattern is
more evident with fewer large precipitates on the surface of the collagen fibers. As the
concentration of Fe3+ increases, more small particles are present on the surface of collagen
fibers.
Further characterization was performed on collagen fibers templated with PASP and
mineralized with an iron Fe2+:Fe3+ ratio of 2:1. The FTIR spectra and XRD pattern are
depicted in Figure 6.3 and Figure 6.4, respectively. The FTIR spectra obtained from pure
collagen and iron oxide mineralized collagen fibers display peaks around 1630 cm-1, 1540
cm-1, and 1200 cm-1. These peaks arise from the different stretching and deformation
modes of the amide bonds in collagen. The amide I peak around 1630 cm-1 results from
C = O stretching; the amide II peak around 1540 cm-1 is due to N-H deformation. The
amide III peak around 1200 cm-1 arises from C-N stretching. Also, for both pure collagen
and mineralized collagen fibers peaks are observed in the 3000 - 2800 cm-1 range and a
broad peak around 3300 cm-1 that arise from C-H and O-H stretches, respectively. Unlike
the pure collagen spectra, collagen fibers mineralized with iron oxide display a small peak
around 560 cm-1 which corresponds to Fe - O stretching. The XRD pattern displays broad
peaks around 20° and 30° due to amorphous scattering of X-rays from collagen. Peaks are
observed around 35.4°, 56.9°, and 62.5° which correspond to the (311), (511), and (440)
reflections of Fe3O4 or γ-Fe2O3 respectively. The distinction between these two phases is
difficult, since γ-Fe2O3 is Fe3O4 but with vacancies at the Fe2+ site. The similarity in crystal
structure results in nearly identical XRD patterns for these materials.
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Figure 6.2: Poly-aspartic acid functionalized collagen fibers mineralized using 4 mM
iron chloride solution with Fe2+:Fe3+ ratios of 1:0 (a), 2:1 (b), 1:1 (c), and 1:2 (d).
6.3.1.1 Synthesis of single collagen fibers
Single collagen fibers were synthesized by controlling the kinetics of collagen polymer-
ization. Collagen polymerization was initiated by mixing a phosphate buffer (pH=7.4)
with acid soluble type I collagen to induce self-assembly of collagen fibers. By monitoring
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Figure 6.3: FTIR spectra of pure collagen (a) and collagen templated with PASP miner-
alized with iron oxide (b) the Fe2+:Fe3+ ratio is 2:1
the turbidity at 313 nm of a polymerizing collagen solution, the morphology of collagen
fibers at different time points within the polymerization process was observed, as shown
in Figure 6.5. The typical kinetic profile is characterized by: (1) a lag phase (constant
absorbance) where collagen monomers laterally aggregate together, (2) polymerization
of collagen fibers characterized by and (3) a plateau indicating complete polymerization
yielding a sigmoidal kinetic curve. The formation of collagen fibers are depicted at different
times in Figure 6.5 (a-c). At the end of the lag phase (30 minutes, Figure 6.5 (a)) collagen
monomers are aggregating together to form collagen fibers. Early in the polymerization
phase (60 minutes, Figure 6.5 (b)) individual collagen fibers ranging from 1 to 10 µm in
length are observed. At the end of the polymerization phase (120 minutes, Figure 6.5 (c)),
a mesh of entangled collagen fibers is observed.
91
Figure 6.4: XRD pattern of collagen templated with PASP mineralized with iron oxide
the Fe2+:Fe3+ ratio of 2:1
6.3.2 Discussion
Mineralized type I collagen is the basic building block of bone and provides an organic
framework for mineralization. Inspired by nature, biomimetic techniques were employed
to mineralize collagen fibers with iron oxide. Poly-aspartic acid was used as a templating
analog to mimic the acidic proteins in the body and to provide an excess of negative
charges to attract positively charged iron ions into the gap zone. To test the hypothesis that
electrostatic attraction between iron ions and negatively charged carboxylates promoted
intrafibrillar mineralization, PAH was grafted to collagen to provide an excess of positive
charges in an attempt to prevent intrafibrillar mineralization through electrostatic repulsion.
As seen in Figure 6.1 (a) and (c), intrafibrillar mineralization was observed in PASP tem-
plated collagen and not in PAH templated collagen, suggesting that electrostatic interaction
aids in intrafibrillar mineralization with iron oxide. The electrostatic interaction with PASP
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Figure 6.5: Top kinetic curve of collagen (0.5 mg/mL) polymerization at pH = 7.4.
Below are TEM images of collagen fibers formed at 30 minutes (a), 60 minutes (b) and
120 minutes (c).
results in a larger concentration of iron ions within the gap zone that can precipitate into
iron oxide when the pH is increased.
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The Fe2+:Fe3+ ratio is important in determining the mineralization pathway. Func-
tionalized collagen fibers were incubated in a 4 mM iron chloride solution with varying
Fe2+:Fe3+ ratios to investigate the effect on mineralization. Iron oxide particles were formed
on the surface and within the gap zone of collagen fibers. When Fe2+:Fe3+ ratio is 1:0,
light d-banding is observed but large crystals are present on the surface of the fibers. The
formation of Fe3O4 or γ-Fe2O3 from a solution of Fe2+ occurs through a dissolution and
re-precipitation process of a green rust precursor which tends to form large hexagonal
shaped crystals in solution.[225] When Fe3+ is present and the concentration of Fe3+ is
less than that of Fe2+, the characteristic d-banding pattern is more evident with fewer
large precipitates in solution. As the concentration of Fe3+ increases, more small particles
are present on the surface of collagen fibers. The presence of Fe3+ promotes nanoparticle
formation of ferrihdyrite in the size range of 2 to 6 nm. Ferrihydrite is more stable than
green rust and precipitates first; these nanoparticles of ferrihydrite aggregate and mature
into Fe3O4 or γ-Fe2O3 through dehydroxylation.[226]
The self-assembly of collagen-fibers is an entropy driven process, which makes difficult
to precisely control fiber length. Through monitoring the kinetics during collagen polymer-
ization, individual collagen fibers between 1 to 10 µm in length and around 100 to 200
nm in width are isolated. Fibers of this size are suitable for tumor targeting applications.
The width of the fibers are small enough to penetrate the tumor, and the length allows the
fibers to be flexible. The above mineralization strategy combined with collagen fibers that
are synthesized through early termination polymerization can yield magnetic nanoworms
for tumor therapy applications.
6.4 Conclusions
Intrafibrillar mineralization of collagen with iron oxide was achieved by templating
collagen fibers with PASP, but templating with PAH resulted in visible intrafibrillar mineral-
ization. The mineralized fibers were magnetically responsive with FTIR and XRD confirming
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the formation of Fe3O4 or γ-Fe2O3. This approach to mineralizing collagen fibers can be
applied to the single collagen fibers isolated during the early stage of polymerization to
synthesis magnetic nanoworms.
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CHAPTER SEVEN
Conlcusions and Future Work
7.1 Conclusions
Ion-exchange was used to synthesize manganese-, iron-, and cobalt-substituted hydrox-
yapatite powders. The synthesized powders were found to be phase-pure with no detectable
second phases, and the incorporation of these ions were sufficient to induce a transition
from diamagnetic behavior for pure HA to a paramagnetic one. DFT calculations of Mn2+,
Fe2+, and Co2+ substitutions were in good agreement with the experimental data. The
results from Chapter 2 underline the power of synergistic theoretical-experimental work
in guiding the rational design of materials. Thus, the DFT calculation could be a useful
tool for predicting physical and magnetic properties of different ion-substituted hydrox-
yapatite powders, and such a tool can be used to guide future studies on the synthesis of
ion-substitute hydroxyapatite with desired properties.
In Chapter 2, Fe2+ had the highest degree of incorporation into HA compared Co2+
and Mn2+, but Mn2+ contributed the most to the final magnetization due to its 5 unpaired
electrons from its [Ar]3d5 electron configuration. Iron displays multiple stable oxidation
state with Fe3+ having a [Ar]3d5 electron configuration. To increase magnetization, FeHA
was synthesized using Fe3+ or a combination of Fe2+ and Fe3+, and the magnetic properties
of such samples are found to be dependent upon the oxidation state of iron and particle size.
The presence of Fe3+ or a combination Fe2+ and Fe3+ resulted in a larger magnetization
compared to Fe2+HA. The combination of Fe2+ and Fe3+ displayed the most promising
magnetic response with a coupled response at low fields, a paramagnetic response at high
fields, and a magnetization comparable to Fe3+ which had the largest mass magnetization
at high fields.
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Transition metals are trace elements and are necessary for normal biological functions.
The synthesized magnetic hydroxyapatite may be suitable for other biomedical applications
where the bulk materials properties of interest. Previous sintering studies have shown that
Fe- and Co-substituted HA is less thermally stable than pure HA, limiting them from being
used in non-load bearing applications.[204, 227] As such, the sintering behavior of MnHA
was compared to pure HA to assess the bulk properties and thermal stability of MnHA.
Decomposition of MnHA into β-TCP and Mn3O4 occurred at 800 °C, while HA pellets started
to sinter at 900 °C with partial decomposition to β-TCP and CaO. The maximum modulus of
rupture achieved for HA and MnHA were 78 and 64 MPa, respectively. The low thermal
stability of MnHA suggests that a faster dissolution rate in vivo than pure HA is expected.
The biocompatibility of FeHA, CoHA, and MnHA were assessed and compared to pure
HA using a proliferation assay and a cytotoxicity assay. Overall, iron- and manganese-
substituted HA powders demonstrated good biocompatibility, which makes them suitable
for potential magnetic applications and other biomaterial applications, such as bone void
fillers. Cobalt-substituted HA is suitable for short-term biomedical applications, such as
serving as a magnetic contrast agent, where the material can be removed rapidly from the
body. Further in vivo testing should be performed for all substituted HA powders.
The synthesized magnetic HAs are suitable for a wide range of magnetic applications
but the rigid nature of these particles may not be well suited for tumor therapy applications.
Magnetic nanoworms were developed by mineralizing type I collagen with iron oxide to
yield semi-flexible and magnetic fibers. Intrafibrillar mineralization of collagen with iron
oxide was achieved by templating collagen fibers with poly-aspartic acid. This approach
to mineralizing collagen fibers can be applied to single collagen fibers isolated during the
early-stage of collagen polymerization to synthesis magnetic nanoworms.
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7.2 Future Work
7.2.1 Application Drivern Testing of Magnetic Hydroxyapatite
MnHA, FeHA, and CoHA have been synthesized and fully characterized. The predomi-
nately paramagnetic response at high magnetic fields indicates that these materials would
be best suited as MRI contrast agents. In vitro determination of T1 and T2 relaxation times
on nanoparticle solutions should be conducted with a clinical MRI machine or nuclear
magnetic resonance spectrometer. After initial measurements, the magnetic HA should be
surface functionalized for specific targeting applications such as bone micro-cracks. MRI
is widely used for the diagnosis of stress fractures since the water molecules in the cracks
provide better contrast compared to conventional X-rays. Thus adding a targeting agent to
aid in the accumulation of magnetic HA within miro-cracks can provide better contrast for
accurate diagnosis, and the excellent bioactivity of the materials may help promote faster
bone healing. MnHA would be of the highest interest for such an application.
7.2.2 Application Driven Testing of Magnetic Nanoworms
A method of mineralizing collagen fibers with iron oxide has been developed, and thus
should be subjected to application-driven testing. This will allow for further evaluation of
the material for tumor therapy or as an MRI contrast agent. Preliminary in vivo testing for
biodistribution and tumor accumulation should be assessed to verify the hypothesis the
semi-flexible nature of the nanoworms can prolong circulation and tumor-site accumulation.
In order to evaluate magnetic nanoworms in vivo, the nanoworms need to be functionalized
with a fluorescent dye, such as Cy5.5, to allow for in vivo tracking.
The high magnetization values of iron oxides have made them popular contrast agents
for MRI when using transverse relaxivity, R2, to provide image contrast. The R2 value
can be measured in vitro using a clinical MRI machine or using an NMR spectrometer.
Magnetic nanoworms are suspended at varying concentrations in solution and a spin echo
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sequence is applied to measure the transverse relaxation time, T2. The R2 value is obtained
by plotting the inverse of T2 versus the iron concentration and fitting the data with a linear
regression where the slope of the regression is R2. The obtained R2 value can be compared
to a commercially available contrast agent, Feridex, which composed of superparamagnetic
iron oxide coating with dextran, for assessing the potential as a T2 contrast agent.
Superparamagnetic iron oxide materials are used capable of increasing the temperature
of a solution via: Brownian relaxation, Néel relaxation, or hysteretic losses. As such, these
materials are widely used for hyperthermia treatment. An alternating magnetic field with
a field strength ranging from 4 to 10 kA m-1 and frequency ranging from 0.2 to 30 MHz
is applied to induce heating. For assessing magnetic nanoworms, the aforementioned
magnetic field and frequency ranges will be used to induce heating of magnetic nanoworms
suspended in a physiological buffer, while recording temperature versus time. From this
data the applicability of nanoworms for hyperthermia can be assessed by calculating the
specific absorption rate (SAR):
SAR =
Cp
m
dT
dt
(1)
where: Cp is the specific heat of the medium, m is the total mass of suspended
nanoworms, and dT
dt
is the rate of change of the temperature. The SAR will be deter-
mined for different field and frequency combinations, and the effect of nanoworm size on
SAR will also be investigated. Again, the obtained SAR will be compared to literature values
as a method to screen the material for hyperthermia.
The high shape anisotropy of magnetic nanoworms may make the material capable of
acting as a nanobot. Magnetic rods/helices/filaments are capable of acting as a nanobot
by applying a uniform rotating magnetic field that allows the user to directly control
the ‘swimming’ motion of the nanobot. The swimming motion may be monitored with
fluorescent microscopy by conjugating a fluorescent dye to the nanoworm. This effect is
desirable for potentially targeting tumors that are in the intraperitoneal cavity. Current
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magnetic targeting techniques rely on the application of static magnetic field gradients
that are easily applied externally, which results in the magnetic material being pulled
towards the surface. The ability of non-invasive magnetic fields to externally manipulate the
‘swimming’ motion may be advantageous at improving penetration of magnetic nanoworms
into tumors and can be used in conjunction with other magnetic therapy techniques i.e.
hyperthermia.
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